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 Abstract 
Milk composition has a dynamic nature, and the composition varies with stage of 
lactation, age, breed, nutrition and health status of the udder. The changes in milk composition 
seem to match the changes in the expression of membrane proteins in secretory mammary 
epithelial cells that are needed for the movement of molecules from blood to milk and vice versa 
(Nouws and Ziv, 1982). Thus, an understanding of transporter expression, function and 
regulation in mammary epithelial cells can provide insight into mammary gland function and 
regulation.  
The goal of this project was to elucidate (molecularly and functionally) the role of drug 
transporters in the barrier function of an epithelial monolayer cultured from an immortalized 
bovine mammary epithelial cell line (BME-UV). To characterize the regulation (expression and 
function) of these drug transporters in BME-UV cells after exposure to cytokine TNF-α for 
selected periods of time. Representative members of drug transporters of the SLC (OCT and 
OAT) and ABC (P-glycoprotein) superfamilies were chosen for this project.  
In the first study, the involvement of a carrier-mediated transport system in the passage of 
organic cation (TEA) and anion (EsS) compounds was elucidated across the BME-UV 
monolayer. In the second study, molecular and functional expression of bOAT isoforms in BME-
UV cells were studied. The final study characterized the effects of cytokine TNF-α on the 
expression and function of P-glycoprotein, an efflux pump, in BME-UV cells. Cytokine TNF-α 
exposure induced the expression of ABCB1 mRNA and increased P-glycoprotein production in 
BME-UV cells, resulting in a greater efflux of digoxin, a known P-glycoprotein substrate, back 
into the apical fluid.  
The expression, function, and regulation of these transporters in the mammary gland has 
important implications for understanding the barrier function of the mammary epithelium and, in 
more specific, for characterizing the role of these transporters in the accumulation and/or 
removal of specific substrates from milk and/or plasma. Moreover, this study provides an in vitro 
cell culture model of mammary epithelium to characterize mammary epithelial cell function 
during inflammation. 
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CHAPTER 1 - INTRODUCTION 
Milk 
People have used milk and milk products from different species of domesticated animals 
as important foods for many years ago (Rusoff, 1970). Milk components provide major 
macronutrients (i.e., protein, fat, and carbohydrate) in a highly digestible form together with the 
micronutrients (i.e., minerals, trace elements, and vitamins) required for growth and development 
(Haug et al., 2007). Milk also contains an array of factors associated with the innate immune 
system that facilitate a neonate’s transition from the relatively sterile environment of the uterus 
to a postnatal environment containing a multitude of microbes, including life-threatening 
pathogens (Ontsouka et al., 2003). Furthermore, milk contains hormones, growth factors, 
cytokines, nucleotides, peptides, polyamines, and enzymes (Haug et al., 2007).  
Milk, also can be a source of xenobiotic exposure in the form of residues, such as drugs, 
natural and artificial hormones, and environmental contaminants that have public health and 
industrial implications. Potential adverse effects of xenobiotic residues to human consumers 
include acute toxicity, carcinogenicity, reproductive effects, and allergic reactions (Gehring et 
al., 2006). Moreover, transporter inhibition by xenobiotics may alter the flux of nutrients across 
the mammary secretory epithelia.  
The Lactating Mammary Gland 
The bovine lactating mammary gland is composed of a branching network of ducts lined 
by epithelial cells and ending in alveoli that are surrounded by a single layer of secretory 
epithelial cells connected by apical junctional complexes. The alveoli are surrounded by 
myoepithelial cells and a vascularized connective-tissue stroma containing lipid-depleted 
adipocytes and fibroblasts (McManaman and Neville, 2003). Milk synthesis occurs within 
clusters of differentiated mammary epithelial cells and is controlled by lactogenic hormones, 
stromal cells, and extracellular matrix interactions (German and Barash, 2002).  
Mammary gland secretion routes 
Various solute transport and secretion processes are involved in milk production. These 
processes also provide pathways for movement of xenobiotic molecules from plasma to milk and 
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vice versa. The exocytotic pathway is the primary mechanism for protein secretion by alveolar 
cells and for secretion of water, lactose, oligosaccharides, phosphate, calcium, and citrate. In the 
lipid secretion process, cytoplasmic lipid droplets are transported to the apical plasma membrane, 
where they are secreted by a unique budding process as membrane-enveloped structures called 
bound milk fat globules. Membrane protein transporters offer another pathway that is composed 
of several distinct, solute-specific mechanisms for transport of monovalent and polyvalent ions 
and small molecules such as glucose and amino acids across the apical and basal membranes of 
cells. The transcytotic pathway allows for vesicular transcytosis of proteins such as 
immunoglobulins and other macromolecules, which involves endocytic uptake of substances at 
the basal membrane, formation and maturation of endosomes, and sorting to lysosomes for 
degradation or to the apical recycling compartment for exocytosis at the apical membrane. And  
the paracellular transport pathway accounts for direct, bidirectional, extracellular movement of 
low-molecular-weight substances and macromolecular solutes between the alveolar lumen and 
the interstitial space during pregnancy, with mastitis states, or after involution (McManaman and 
Neville, 2003).  
Mammary secretory epithelium as a barrier 
Tight junctions between mammary epithelial cells limit the paracellular movement of 
molecules, but water-filled pores could offer a pathway for hydrophilic molecules to enter milk 
by bulk flow. Transcellular movement is another option that would require molecules to pass 
through the lipophilic apical and basolateral membranes of mammary epithelial cells. Such 
movement would be driven by the concentration gradient between plasma and milk and may be 
facilitated by ion- or substrate-selective transporters. Alternatively, xenobiotics could enter milk 
independent of the concentration gradient by one of the primary or secondary active transport 
mechanisms, some of which are important for the transfer of essential nutrients from plasma to 
milk (Berlin and Briggs, 2005; Wilson et al., 1980). Thus, the mammary secretory epithelium, 
which plays an important role in separating and maintaining differences between blood and milk, 
is likely a significant barrier to the movement of some xenobiotics into milk (McManaman and 
Neville, 2003).    
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CHAPTER 2 - LITERATURE REVIEW 
 
Numerous compounds, such as pharmaceuticals, environmental substances, and 
metabolites of both exogenous and endogenous origins are charged at physiological pH 
(Miyazaki et al., 2004). The lipophilic plasma membrane surrounding animal cells impedes the 
passive diffusion of such charged molecules. Nevertheless, these substances can be concentrated 
in tissues to exert either therapeutic or toxic effects. The mechanism of cellular entry necessarily 
involves permeation through specialized membrane proteins called transporters.  
In recent years, it has been recognized that transporters are important determinants of the 
disposition of endogenous, exogenous compounds and their metabolites in the body by altering 
their absorption, distribution, and elimination. Transporters also have been implicated in drug-
drug interactions and toxicities (Audus et al., 1990). For example, P-glycoprotein is expressed in 
the intestinal tract at the brush border of epithelial cells, where it limits absorption of molecules 
after oral administration (Thiebaut et al., 1987). Moreover, different secretory epithelia, such as 
renal and hepatic epithelia, express a variety of membrane transporters, including members of 
organic anion transporters (OAT), organic cation transporters (OCT), multidrug resistance-
associated protein (MRP), and P-glycoprotein (Borst et al., 2000; Kim, 2002; Klein et al., 1999; 
Koepsell, 1998; Sekine et al., 2000). These transporters play important roles in movement of 
molecules across the epithelial monolayer by facilitating uptake of molecules or efflux them 
back to the donor fluid.   
Membrane Protein Transporters 
Major membrane transporters have been classified into the solute carrier (SLC) and ATP-
binding cassette (ABC) superfamilies (Goodman et al., 2006).  
Solute carrier (SLC) superfamily 
The SLC superfamily includes genes that encode facilitated transporters and ion-coupled 
secondary active transporters that reside in various cell membranes. Forty-three SLC families 
with approximately 300 transporters have been identified in the human genome. Many serve in 
drug absorption and disposition processes (Goodman et al., 2006). Within the SLC superfamily, 
the SLC22 family, which has polyspecific members, has been identified as mediating the 
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transport of a variety of structurally diverse organic anion and cation compounds. The SLC22 
family consists of the following major transporter subfamilies: OAT (Sweet et al., 2001), OCT, 
the carnitine transporter (Wu et al., 1998), and the urate anion-exchanger (Enomoto et al., 2002). 
Organic anion transporters (OAT) 
Four significant mammal OAT isoforms have been identified;  OAT-1 (Sekine et al., 
1997), OAT-2 (Sekine et al., 1998a), OAT-3 (Kusuhara et al., 1999), and OAT-4 (Cha et al., 
2000). These OAT subfamily members differ in substrate selectivity and localization. For 
instance, OAT-1, OAT-2, and OAT-3 were reported to be involved in uptake of various 
endogenous and exogenous substances via the basolateral membrane, whereas OAT-4 was 
reported to be involved in either uptake or excretion of different substances via the apical 
membrane (Giacomini et al., 2010; Miyazaki et al., 2004; Sekine et al., 2006; Takeda et al., 
2001).  
OAT-1 and OAT-3 have distinct substrate selectivity. For example, OAT-1 has high 
affinity for the classical renal OAT substrate P-aminohippuric acid (Pah), but OAT-3 has no 
affinity for Pah. In contrast, OAT-3 has high affinity for estrone sulfate (EsS), whereas OAT-1 
has only a very slight affinity for EsS (Dantzler and Wright, 2003). Acetylsalicylate (Sal) is a 
selective substrate for OAT-2 (Miyazaki et al., 2004; Sekine et al., 2006), which mediated 
saturable uptake of Sal when expressed in Xenopus laevis oocytes (Sekine et al., 1998a). Also, 
EsS has been reported to interact, with high affinity, with OAT-4 (Sekine et al., 2006).  
The OAT have pharmacological significance because of their selectivity to a wide variety 
of substrates, including clinically important compounds such as β-lactam and sulfonamide 
antibiotics, loop and thiazide diuretics, nonsteroidal anti-inflammatory drugs, antiviral agents, 
and environmental pollutants (e.g., anionic herbicide 2,4-dichlorophenoxyacetic acid) (Sekine et 
al., 2000; Sweet et al., 2001). All OAT isoforms possess a common structural feature12 putative 
transmembrane domains (TMD) with large hydrophobic loops between the first and second and 
between the sixth and seventh TMDs (Sekine et al., 2000). 
Organic cation transporters (OCT) 
The OCT subfamily contains three isoforms of facilitated transporters called OCT-1, 
OCT-2, and OCT-3 (Choi and Song, 2008). These OCT isoforms mediate the transport of small, 
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hydrophilic compounds with at least one positively charged amine moiety at physiological pH. 
Selective substrates for OCT include the model substrate tetraethylammonium (TEA), clinically 
important therapeutic drugs (e.g., metformin, procainamide, cisplatin, citalopram, cimetidine), 
and endogenous compounds such as dopamine and norepinephrine (Gorboulev et al., 1997; 
Koepsell et al., 2007; Zhang et al., 1997).  
Tissue distribution of the OCT isoforms is distinctive. For example, OCT-1 is primarily 
expressed in the sinusoidal membrane of hepatocytes and is present in the epithelial membrane 
of the intestine at a low level, whereas OCT-2 is primarily expressed in the basolateral 
membrane of the kidney proximal tubules. Tissue distribution of OCT-3 is widespread and 
includes the brain, heart, skeletal muscle, blood vessels, placenta, and liver (Koepsell et al., 
2007). Transcripts for OCT-1 and OCT-3, but not OCT-2, have been detected in the lactating rat 
mammary gland (Gerk et al., 2001b). The OCT isoforms have 12 TMD with a big extracellular 
loop with glycosylation sites between the first and second TMDs, and between the amino and 
carboxyl termini on the cytoplasmic side (Ciarimboli and Schlatter, 2005). 
ATP-binding cassette (ABC) superfamily 
Most ABC proteins are primary active transporters, which rely on ATP hydrolysis to 
actively pump their substrates across membranes. There are 49 known genes for ABC 
transporters that can be grouped into seven subclasses or families (ABCA to ABCG) (Goodman et 
al., 2006). One of the most recognized transporters in the ABC superfamily is P-glycoprotein (the 
MDR1 gene product, which is also classified as ABCB1), an ATP-driven efflux pump located on 
the apical side of cells (Chandra and Brouwer, 2004; Kim, 2002; Masereeuw et al., 2003; 
Mealey, 2004).  
P-glycoprotein plays an important role in xenobiotic absorption, distribution, and 
elimination as a result of its tissue distribution and cellular localization. For example, P-
glycoprotein is expressed at the brush borders of epithelial cells in the intestinal tract, where it 
limits absorption after oral administration and facilitates secretion into the intestinal lumen 
(Thiebaut et al., 1987). In the liver, P-glycoprotein is expressed at the canalicular (apical) surface 
of hepatocytes, where it facilitates excretion of drugs and toxins (or their metabolites) into the 
bile (Chandra and Brouwer, 2004). In the kidney, P-glycoprotein is expressed on the apical 
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surface of the epithelial cells of the proximal tubules, where it mediates elimination of 
endogenous metabolic waste products and xenobiotic metabolites (Masereeuw et al., 2003). At 
biological barriers such as the BBB, P-glycoprotein is expressed on the luminal plasma 
membrane of the capillary endothelium, where it prevents passage of drugs and toxins across the 
capillary endothelium into the brain (Fricker and Miller, 2004).  
P-glycoprotein mediates active cellular efflux of a large number of drugs and toxic 
compounds and transports many structurally and pharmacologically unrelated hydrophobic 
compounds including anticancer agents, immunosuppressive agents, calcium channel blockers, 
β-blockers, cardiac glycosides, pesticides, anthelmintics, and antibiotics (Marzolini et al., 2004; 
Sakaeda et al., 2002; Schwab et al., 2003). P-glycoprotein is a large (170 Kd) homodimer with 
two TMD (each with six helices) and two nucleotide-binding domains (NBD) (Rosenberg et al., 
2005). Higgins and Gottesman (1992) proposed a “hydrophobic vacuum cleaner” model for 
substrate interactions with P-glycoprotein. They suggested that substrates partition into the lipid 
bilayer before interacting with P-glycoprotein and being expelled into the extracellular aqueous 
phase. There is substantial experimental evidence to support this model, and it is widely accepted 
(Eckford and Sharom, 2009).  
Transporter expression in mammary epithelial cells 
During lactation, the mammary gland epithelium is differentiated into a highly active 
secretory tissue (Alcorn et al., 2002). mRNA transcripts for 19 different transporter genes have 
been reported in non-lactating and lactating human mammary epithelia. For example, OCT, 
OCTN, OATP, MRP, and P-glycoprotein are expressed by human mammary epithelial cells at 
levels comparable to those in liver and kidney (Alcorn et al., 2002; Ito et al., 2005). Using RT-
PCR, different transporters were detected in rat whole mammary gland including Mdr1a, Mdr1b, 
Mrp1, Oct1, Pept1, and Petpt2 (Gilchrist and Alcorn, 2009) . 
Although several membrane transporters have been extensively characterized in rat, 
mouse, and human (Alcorn et al., 2002; Buist and Klaassen, 2004; Matsushima et al., 2005; 
Sekine et al., 1997; Takeda et al., 2001), information on bovine membrane transporters is 
limited. To our knowledge, the only transporters that have been characterized in bovine 
mammary gland are breast cancer resistance protein (BCRP) (Jonker et al., 2005), glucose 
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transporters (Zhao and Keating, 2007), fatty acid transporter (Bionaz and Loor, 2008), lipid 
transporters (Mani et al., 2009), and monocarboxylate transporters (Kirat and Kato, 2009).  
However, other membrane transporters have been reported in different bovine tissues: 
monocarboxylate transporters in adrenal gland (Kirat et al., 2009), cationic amino acid 
transporter and nucleoside transporters in small intestinal epithelia (Liao et al., 2008; Liao et al., 
2009), P-glycoprotein in brain microvessel endothelial cells (Perloff et al., 2007), prostaglandin 
transporter in uterus and fetal membranes (Banu et al., 2005), carnitine transporters in brain 
capillary endothelial cells (Berezowski et al., 2004), and serotonin transporter in many tissues 
such as placenta, lung, kidney, and liver (Mortensen et al., 1999). 
Regulation of mammary epithelial barrier functions 
Milk composition has a dynamic nature, and the composition varies with stage of 
lactation, age, breed, nutrition and health status of the udder (Ontsouka et al., 2003). The changes 
in milk composition seem to match the changes in the expression of membrane proteins in 
secretory mammary epithelial cells that are needed for the movement of molecules from blood to 
milk and vice versa. 
Pregnancy and lactation 
The mammary gland undergoes dramatic functional and metabolic changes during the 
transition from late pregnancy to lactation. Rising estrogen levels in blood circulation during 
early stages of pregnancy in non-lactating cows stimulate mammary ductal morphogenesis, 
whereas the combined action of estrogen, progesterone, and prolactin induces the proliferative 
phase of alveolar morphogenesis (Neville et al., 2002). Lactogenesis, the initiation of milk 
synthesis and secretion, has two stages. Stage I begins in mid-pregnancy with the progressive 
expression of many, but not all, of the genes involved in synthesis of milk components. Stage II 
is initiated around parturition and characterized by closure of tight junctions between epithelial 
cells and secretion of colostrums, and then milk (Neville et al., 2002).  
Besides the cellular proliferation and differentiation of mammary epithelium into a 
polarized epithelium (Neville et al., 2002), significant changes also occur in the transporter array 
that allow transport of nutrients and endogenous compounds across the mammary epithelium 
(Alcorn et al., 2002). This altered expression array includes changes in transporter expression 
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levels of members of the ABC and the SLC superfamilies (Alcorn et al., 2002). Using RT-PCR, 
significant changes in transporter expression were observed in rat whole mammary gland during 
late gestation and different periods of lactation; these changes were stage dependent and 
transporter dependent (Gilchrist and Alcorn, 2009). Furthermore, expression profiles of 
approximately 23,000 gene transcripts in bovine mammary tissue on day 5 before parturition and 
day 10 after parturition were analyzed using microarray analysis; 389 transcripts (1.6%) were 
significantly differentially expressed at the two stages (Finucane et al., 2008). Of the transcripts 
with significant changes, 105 were upregulated and 284 were downregulated. The main 
upregulated genes were involved in milk synthesis and transport activity (amino acid, glucose, 
and ion transporters), whereas the main downregulated genes were related to cell cycle and 
proliferation (cyclins, cell division cycle associated proteins, etc.). 
Pathological conditions (Bovine mastitis) 
Bovine mastitis, a major disease affecting dairy cattle worldwide and a major source of 
residues found in milk supplies (Booth and Harding, 1986), results from inflammation of the 
mammary gland. Inflammation severity can be classified into subclinical, clinical, and chronic 
forms, and the degree of severity depends on the nature of the causative pathogen as well as age, 
breed, immunological health, and lactation state of the animal (Viguier et al., 2009). The primary 
cause of mastitis is a wide spectrum of bacterial strains, however, viral, algal, and fungal mastitis 
also have been reported (Pyorala, 2003).   
Mastitis can be associated with changes in mammary epithelial barrier functions that alter 
milk composition. The most severe alterations in milk composition due to subclinical mastitis, 
next to high somatic cell count (SCC), are elevated quantities of free fatty acids, a reduction in 
casein and concomitant increase in whey protein; a reduction in lactose concentration; changes in 
the concentration of minerals such as sodium, chloride, potassium, and calcium, and an increase 
in milk pH. The changes in milk constituents are caused by chemical mediators of inflammation 
(e.g., histamine, cytokines), bacterial toxins, and the activity of enzymes in milk (Brandt et al., 
2010). 
Proinflammatory cytokines 
The mammary gland is protected by a variety of defense mechanisms, which can be 
separated into two distinct categories: innate immunity and specific immunity (acquired). 
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Interactions between these two branches of host defense are regulated by cells of the immune 
system and soluble factors, including cytokines (Sordillo et al., 1997). Cytokines are small 
proteins (less than 50 KDa) that act as intracellular communication signals in hematopoiesis, 
stress, inflammation, immunity, and tissue repair (Belardelli and Ferrantini, 2002). 
Proinflammatory cytokines regulate the activity of immune cells in the pathophysiology of 
bovine mastitis by increasing the bactericidal capacity of macrophages and neutrophils, 
promoting recruitment of neutrophils toward the site of infection, and inducing maturation of 
dendritic cells (Oviedo-Boyso et al., 2007).  
Major groups of cytokines reported during intramammary infection of dairy cows include 
interleukin (IL), colony-stimulating factor (CSF), interferon (IFN), and tumor necrosis factor 
(TNF) (Alluwaimi, 2004; Bannerman, 2009). TNF-α, which has been detected and monitored in 
normal and infected bovine mammary glands, is produced by macrophages, neutrophils, and 
epithelial cells. Different levels of TNF-α have been detected in all lactation, involution, and 
periparturient periods except a short period before parturition, when it drops below a detectable 
level (Alluwaimi and Cullor, 2002). In natural coliform mastitis, experimental Escherichia coli 
infection, and a lipopolysaccharide-infused mammary gland model, TNF-α was significantly 
increased in milk and serum (Nakajima et al., 1997; Persson Waller et al., 2003). 
Several in vitro and in vivo investigations have shown that inflammation and 
proinflammatory cytokines such as TNF-α alter the expression of membrane transporters 
(Evseenko et al., 2007; Hirsch-Ernst et al., 1998; Wedel-parlow et al., 2009). A significant 
increase in ABCB1 mRNA and protein production of P-glycoprotein was observed in 
immortalized human brain capillary endothelial cells incubated with TNF-α (Poller et al., 2009). 
Effects of these cytokines appear at different levels of expression including transcriptional, 
translational, and post-translational (Englund et al., 2007; Sukhai et al., 2000; Theron et al., 
2003). 
Other factors 
Additional factors such as drugs, toxic agents, and heat shock can modulate the 
expression of membrane transporters (Kim et al., 2003; Sukhai et al., 2000). It has been reported 
that the heat shock element may be involved in the alterations of ABCB1 transcription rates 
through pathways that are dependent upon protein kinase A (PKA) and the raf oncogene (i.e. raf 
activation by heat shock, which stimulates the heat shock response, resulted in an induction of P-
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glycoprotein activity, whereas inhibition of PKA activity, blocked the heat shock potentiation of 
P-glycoprotein activity) (Kim et al., 1996). On the other hand, chronic furosemide or 
hydrochlothiazide infusion caused increases in OAT-1 protein abundance in rat kidney (Kim et 
al., 2003). However, downregulation of OAT-1 and OAT-3 with impaired secretion of Pah was 
observed after ischemic acute renal failure in rats (Schneider et al., 2007).  
Methods to assess transporter expression, function, and regulation 
Providing assay systems that can be used for studying the role of transporters in 
movement of xenobiotics across biological barriers is becoming increasingly important. These 
systems can provide insight into function and regulation of these transporters and, possibly, act 
as screening tools for predicting drug-drug or drug-nutrient interactions. Currently available 
systems are described in the following paragraphs.  
Membrane-based assay system 
Inverted plasma membrane vesicles are equivalent to the hepatic microsomes used for in 
vitro drug metabolism studies and are used primarily to obtain information on affinity (Km) and 
capacity (Vmax) of various transporters to selected solutes. The principal advantage of the vesicle 
approach is evaluating membrane-specific drug transport without the effects of metabolism as a 
complicating factor (Hopfer, 1978; Lever, 1980). The major disadvantages of this assay system 
are vesicle heterogeneity, back diffusion of hydrophobic compounds, and the high degree of 
background binding to cell membranes in vesicle or cellular systems when uptake or efflux of 
hydrophobic compounds needs to be measured (Keppler et al., 1998).  
Cell-based assay systems 
These systems can be used in mechanistic studies to assess transport mechanisms, the 
rate-limiting step in transepithelial transport, and transporter-based drug-drug interactions. 
Polarized cell lines without recombinant transporters 
Wild-type cell lines provide the advantage of expressing multiple transporters 
simultaneously. Under appropriate culture conditions, some wild-type cell lines produce 
polarized monolayers, thus allowing for evaluation of molecular flux in both directions; apical-
to-basolateral (Ap-to-BL), and BL-to-Ap. However, it is important that the chosen cell culture 
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model displays some of the morphological and functional properties that are representative of the 
corresponding in vivo cell layers. 
Single- and double-transfected cell lines 
A recombinant transporter that are stably, achieved by integration of the gene of interest 
into the target cell’s chromosome, or transiently, not necessarily indicates integration of the gene 
into the host chromosome and is not passed onto the next generation, expressed in various cell 
lines can be used to characterize compound transport across the epithelial monolayer. Cultured 
cell lines used to study compound-transporter interactions include cell monolayers such as 
MDCK, LLC-PK1, and HEK293. These monolayers can be used to assess uptake and efflux by 
single recombinant transporters and obtain kinetic measurements (Giacomini et al., 2010).  
Polarized cells that stably express multiple transporters (e.g., a recombinant uptake 
transporter in their basolateral membrane and an efflux transporter in their apical membrane) 
also have been developed (Matsushima et al., 2005; Sasaki et al., 2004). These cell lines may 
overcome the limitations of certain single-transfected cells that often lack the endogenous uptake 
or efflux transporters to provide a complete mechanism for transcellular transport of a molecular 
entity.  
Primary cell-based assay 
Primary cells are derived from intact tissues, which, at the time of isolation, express the 
full complement of transporters present in a given tissue. Thus, primary cells may be used to 
study drug disposition and clinically relevant drug interactions. However, because most primary 
cell cultures have a limited lifespan and can adapt to culture conditions over time, strict 
definition of culture methods is required to ensure proper polarization (Giacomini et al., 2010). 
Furthermore, primary cultures are often heterogeneous and detailed information on their 
morphology is lacking (Zhao et al., 2010).  
Intact organ 
Isolated whole-organ perfusions have an advantage in that they maintain the cellular 
architecture and in vivo environment of the organ. In the case of the mammary gland, which is 
grounded on interactions between milk-producing cells and their extracellular matrix 
environment (Howlett and Bissell, 1993; Parry et al., 1987), a whole-organ perfusion would 
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seem like a reasonable system. But this technique also has disadvantages: it might require 
specialized surgical techniques, it has a low throughput capability, and the perfusion rate must 
match organ blood flow to maintain physiological conditions (Heyman et al., 2002). 
In vivo models  
Numerous transporter-gene knockout and naturally occurring transporter-deficient animal 
models have been characterized, and their commercial availability has been increasing steadily. 
Limitations of knockout and mutant models include species, strain, diet, and housing condition 
differences, as well as compensatory mechanisms, (Klaassen and Lu, 2008). All of these 
variables should be considered carefully in data interpretation and in attempts to extrapolate 
findings across species.  
Need for an in vitro model 
Use of cell culture in vitro model systems as an alternative to animal experimentation in 
basic science research has recently received more attention as a possible screening tool for 
xenobiotic transport and metabolism studies (Bock et al., 2004; Franke et al., 2000; Gruber and 
Hartung, 2004). Compared with animal systems, in vitro model systems are more cost-effective, 
have higher throughput, allow for more replicates (stronger statistical power), the mechanism of 
transport can be evaluated, early signs of cell toxicity can be recorded, and pathological 
conditions can be induced and molecular mechanisms evaluated (Lundquist et al., 2002). Most 
importantly, in vitro studies may provide scientists with new, basic information about transport 
mechanisms in biological barriers that will permit them to develop novel strategies for targeting 
drugs to specific tissue compartments or enhancing drug permeability through now-impermeable 
biological barriers (Audus et al., 1990). 
Cell culture in vitro model 
In vitro culture models of polarized epithelial cells grown on permeable supports are used 
by the pharmaceutical industry to study the movement of drugs across various epithelial barriers. 
These models can be used for mechanistic studies to assess transport mechanisms, the rate-
limiting step in transepithelial transport, and transporter-based drug-drug interactions. These 
models are considered to be good predictors of the rate and extent of movement of compounds 
across specific epithelial barriers, as they incorporate not only simple passive diffusion but also 
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the various other transport mechanisms by which compounds may cross the epithelial barrier 
(Lehr, 2002).  
Primary epithelial cell cultures and several epithelial cell lines, developed from mice, 
rats, cows and humans, have been used to study drug movement across epithelial monolayers, 
responses to inflammatory mediators, and other functions of epithelial barriers (Al-Bataineh et 
al., 2009; Bisbee, 1981; Bisbee et al., 1979; Gordon et al., 2000; Guidry et al., 1998; Huynh and 
Pollak, 1995; Huynh et al., 1991; Kimura et al., 2006; Taketani and Oka, 1986; Zavizion et al., 
1996; Zucchi et al., 1999). One of the most extensively used cell lines is a human colorectal 
adenocarcinoma cell line (Caco-2). Caco-2 undergoes spontaneous enterocytic differentiation 
with time in culture and thus forms monolayers of differential epithelial cells joined by 
intercellular tight junctions (Sambuy et al., 2005). These cells exhibit remarkable morphological 
and biochemical similarity to the small intestinal columnar epithelium; they are extremely useful 
for mechanistic studies of drug absorption and are widely used in pharmaceutical companies as 
an absorption screening assay for pre-clinical drug selection (Maubon et al., 2007).  
Another well-known epithelial cell line is MCF-7, a human mammary epithelial cell line 
that was isolated from a patient with breast cancer (Horwitz et al., 1975b). Lines of normal 
human mammary epithelial cells include MCF-10 and T-HME (Kim et al., 2002;Lee et al., 
2007). However, these cell culture models may not be appropriate for evaluation of the specific 
transport processes in the bovine because of transporter expression is species and organ 
dependent (McNamara et al., 1992; Sekine et al., 1998a; Sekine et al., 1998b). Therefore, a 
bovine-specific culture model of mammary epithelial cells is essential to evaluate the possible 
carrier-mediated transport of drugs between plasma and milk. 
Besides primary culture, there exist some immortalized bovine mammary epithelial cell 
(BMEC) lines (Huynh and Pollak, 1995; Huynh et al., 1991; Zavizion et al., 1996). The MAC-T 
epithelial cell line was established from primary bovine MEC by immortalization with SV40 
large-T antigen (Huynh et al., 1991). The MAC-T cells possess insulin-like growth factor-I (IGF-
I) receptors and respond to IGF-I in terms of increased DNA synthesis (Woodward et al., 1996; 
Zhao et al., 1992). This cell line has been used mainly to study IGF-I metabolism (Robinson et 
al., 2000). However, the expression of milk protein by these cells is not stable. Furthermore, 
MAC-T cells do not respond to epidermal growth factor (EGF), a known modulator of mammary 
function (Zavizion et al., 1996). Another bovine cell line has also been generated; the HH2A 
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which is a spontaneously immortalized bovine mammary epithelial cell line. The HH2A cells 
express the gene encoding for mammary derived growth inhibitor (MDGI) and contain keratin 
intermediate filaments and desmosomes that make it useful in investigations of the roles of cell-
cell interactions in regulation of epithelial cell proliferation (Huynh and Pollak, 1995). However, 
the synthesis of casein, the predominant milk protein, has not been reported for this HH2A cells 
(Zavizion et al., 1996). Another BME cell line is L-1 which is also a spontaneously immortalized 
bovine mammary epithelial cell line that may only synthesize a spot of β-lactoglobulin when 
cultured on Matrigel, but the synthesis of casein, the predominant milk protein, has not been 
reported for this cell line as well (German and Barash, 2002). 
The BME-UV cell line was established from primary bovine mammary epithelial cells by 
stable transfection with a plasmid encoding the thermolabile large T-antigen. The BME-UV cells 
expressed functional markers such as microvilli and desmosomes and biochemical markers of 
mammary epithelial cells such as a repertoire of cytokeratins. Moreover, the BME-UV cells are 
capable of synthesizing α-lactalbumin and αs1-casein. Also, the BME-UV cells showed 
enhanced proliferation in the presence of epidermal growth factor (EGF) and insulin-like growth 
factor I (IGF-I). The BME-UV cell line is the only known bovine mammary epithelial cell line 
responsive to EGF (Zavizion et al., 1996). Furthermore, this cell line establish a cell polarity 
with well-formed tight junctions between adjacent cells, exhibit a transepithelial electrical 
resistance, and show responsiveness to steroid hormones (Quesnell et al., 2007; Schmidt et al., 
2001). It has been also shown that BME-UV cells express metabolizing enzymes that have 
catalytic activity (Caruso et al., 2009), suggesting BME-UV cell line as a potential in vitro model 
for studying biotransformation in bovine mammary gland. The relatively low monolayer 
integrity, long cell culture period (14 days), and the expensive components of the media are the 
main disadvantages of this cells line.  
Conclusion 
The roles of members of the solute carrier (SLC) and ATP-binding cassette (ABC) 
superfamilies in molecule transport have been elucidated in many polarized epithelial barriers 
(e.g., kidney, liver, blood-brain barrier, and intestine) in many species. But despite the large 
amount of effort devoted to evaluating these transporters, limited work has been conducted to 
evaluate the roles of these transporters in the mammary gland. Research described in this 
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dissertation was focused on the carrier-mediated transport processes of xenobiotic molecules and 
provides perspective on how the proinflammatory cytokine TNF-α regulates expression and 
function of these transporters. 
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Abstract 
There is ongoing concern about the potential adverse effects of xenobiotic residues in 
cows' milk to the human consumer. Although drugs that are intentionally administered to 
lactating dairy cattle are rigorously regulated to prevent harmful residues, there are numerous 
other potential sources of exposure that are not as easily controlled. For example, cattle may be 
exposed to mycotoxins, pesticides and/or persistent organic pollutants through feed, water and 
inhalation of polluted air. Accurate estimates of the rate and extent of excretion of these 
compounds into milk is important to assess the risk of exposure through cows' milk. In the 
present study, the expression of carrier mediated transport processes in cultured monolayers of 
an immortalized bovine mammary epithelial cell line (BME-UV) was determined using a flow-
through diffusion cell system, selective substrates and inhibitors of organic cation transporters 
(OCT) and organic anion transporters (OAT). The basal-to-apical (BL-to-Ap) flux of 
tetraethylammonium and estrone sulfate significantly exceeded their flux in the opposite 
direction. The addition of selective inhibitors to the donor compartment significantly decreased 
the BL-to-Ap flux of either selective substrate. These results suggest that both OCT and OAT are 
functionally expressed by BME-UV cells. 
Introduction 
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Milk and milk products from different species of domesticated animals have been used as 
important foods by man for thousands of years (Rusoff, 1970). The United States produced more 
than 185 billion pounds of milk in 2007. Approximately 60% or 111 billion pounds of this total 
was consumed as fluid milk (USDA, 2007). This high level of consumption, often by vulnerable 
sub-populations such as infants and children, makes it very important that milk is safe and free of 
potentially harmful residues. Potential adverse effects of xenobiotic residues to the human 
consumer include acute toxicity, carcinogenicity, teratogenicity, allergic reactions and the 
selection of resistant bacteria (Gehring et al., 2006; Przyrembel et al., 2000). Residues can also 
interfere with the manufacture of dairy products, such as cheese,  which depend on bacterial 
fermentation for their production (Molina et al., 2003).  
An integral part of ensuring that consumed milk is the conduct of mandatory residue 
depletion studies prior to the approval of drugs for use in lactating dairy cattle (FDA). These 
studies ensure that there are no harmful residues as a result of intentional administration of 
veterinary drugs, according to label instructions. But there are numerous other potential sources 
of harmful residues in milk, including exposure to environmental contaminants through feed, 
water and inhaled air, as well as extra-label use of veterinary drugs. Drug-drug and drug-feed 
interactions may also lead to changes in the rate and extent of xenobiotic excretion into milk. 
Environmental contaminants that may result in harmful milk residues include mycotoxins, heavy 
metals, pesticides and persistent organic pollutants such as polychlorinated biphenyls and dioxins 
(Markaki and Melissari, 1997; Patra et al., 2008; Przyrembel et al., 2000; Westin, 1993) 
Milk concentrations of xenobiotic residues, and therefore the risk of exposure to the 
human consumer, depend on the rate and extent to which these compounds are excreted into the 
milk. This, in turn, is dependent on the physicochemical properties of the xenobiotic and how 
these interact with the  biological environment (Gehring and Smith, 2006). Several authors have 
developed mathematical models to predict milk concentrations based compounds’ 
physicochemical properties, including lipophilicity, pKa and molecular weight (Atkinson and 
Begg, 1990; Begg et al., 1992). The extent of ionization and protein binding are also considered 
in these models. Although these models are successful in predicting exposure to some 
compounds, in vivo studies in a variety of species have identified drugs that are present in milk at 
higher than predicted concentrations. Among these are acyclovir (Lau et al., 1987), cimetidine 
(McNamara et al., 1996) and nitrofurantoin (Kari et al., 1997). Contribution of carrier mediated 
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transport systems to the movement of xenobiotics from plasma to milk is the most likely 
explanation for these higher concentrations  (Kimura et al., 2006). Messenger-RNA coding for 
different members of organic anion and organic cation transporter families have been isolated 
from human mammary epithelial cells purified from pooled fresh breast milk samples (Alcorn et 
al., 2002) or from cell cultures (Kimura et al., 2006).  
In vitro culture models of polarized epithelial cells grown on permeable supports are used 
by the pharmaceutical industry to study the movement of drugs across various epithelial barriers. 
Models have been developed for the gut, respiratory and ocular epithelia, amongst others. These 
models are considered to be good predictors of the rate and extent of movement of compounds 
across specific epithelial barriers, since they incorporate not only simple passive diffusion, but 
also the various other transport mechanisms by which compounds may cross the epithelial 
barrier (Lehr, 2002). It is, however, important that the chosen cell culture model displays some 
of the morphological and functional properties that are representative the corresponding in vivo 
cell layers were established (Wilson, 1990). Since the most likely rate-limiting barrier to 
xenobiotic movement from plasma to milk is the mammary secretory epithelium (Nguyen and 
Neville, 1998; Shennan and Peaker, 2000), Kimura et al.(2006) investigated the feasibility of 
developing an in vitro model of this barrier using a human mammary epithelial cell line 
(HMEC). Kimura et al. (2006) found OCTs to be expressed in this cell line. Among these is the 
human mammary epithelial cell (HMEC) culture model that was developed by Kimura et al., 
(2006). To the authors’ knowledge, a model using bovine mammary epithelial cells has not yet 
been developed, despite the importance of bovine milk as a source of human nutrition, especially 
for children and infants. The study described in this manuscript was designed to investigate 
functional expression of OATs and OCTs in the mammary epithelial cell line (BME-UV) which 
may play a role in the movement of xenobiotic agents from plasma to milk as well as from milk 
to plasma. Some of these agents are benzylpenicillin, tetracycline, salicylate, acyclovir, 
cidofovir, and p-aminohippurate which were classified as substrates for OAT, while verapamil, 
pyrilamine, quinidine, ganciclovir and cimetidine were classified as substrates for OCT (Sai and 
Tsuji, 2004).  
Materials and Methods 
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Chemicals 
Tetraethylammonium bromide, estrone sulfate, probenecid, 1,1-Diethyl-2,2-cyanine 
iodide, disodium ethylenediaminetetraacetic acid and Perdrogen® (30% H2O2 w/w) were 
purchased from Sigma-Aldrich (St Louis, MO, USA). [3H]-mannitol (20 Ci/mmol), [14C]-
mannitol (55 mCi/mmol), [14C]-tetraethylammonium bromide (55 mCi/mmol) and [3H]-estrone 
sulfate (50 Ci/mmol) were purchased from American Radiolabelled Chemicals, Inc. (St Louis, 
MO, USA). Biosol® and Bioscint® were purchased from National Diagnostics, Inc. (Atlanta, GA, 
USA). 
Cell culture 
The BME-UV cells were cultured under conditions similar to those described previously 
(Quesnell et al., 2007a; Quesnell et al., 2007b; Schmidt et al., 2001). Briefly, stock cultures were 
grown to 65–75% confluency in 25 cm2 plastic culture flasks (Corning, Inc., NY, USA). Cells 
were dissociated for passage using a solution containing 0.25% trypsin and 2.65 mm disodium 
ethylenediaminetetraacetic acid (EDTA, Gibco) in phosphate-buffered saline. Then, dissociated 
and dispersed cells were seeded on permeable polyester inserts, Transwells® (Corning, Inc.). 
These inserts measure 24 mm in diameter and have a pore size of 0.4 μm. Typical bovine 
medium (TBM), which contains little lactose and has concentrations of electrolytes that closely 
mirror serum, bathed the basolateral aspect of the cells throughout all experiments. The apical 
aspect was exposed to apical bovine medium (ApM) of low electrolyte-high lactose composition 
that resembles the ionic composition of milk. Composition of TBM and ApM were reported 
previously (Quesnell et al., 2007a; Quesnell et al., 2007b; Schmidt et al., 2001). ApM (1.5 mL) 
and TBM (2.5 mL) were added to the top and bottom compartments that were formed by the 
monolayers of cells respectively. The cells were incubated at 37 °C in a humidified atmosphere 
containing 5% CO2. Media on both the apical and basolateral aspects of the cells were refreshed 
daily. Cells were maintained in culture on permeable supports for 2 weeks to form a confluent, 
polarised and electrically tight monolayer. 
Flow-through diffusion cell system 
The confluent monolayer of BME-UV cells on the permeable Transwell® support was 
mounted as a barrier membrane in a flow-through diffusion cell system (Permegear®, Bethlehem, 
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PA, USA). The system had 14 diffusion chambers, automated receptor fluid collection and a 
high precision multichannel dispenser (Ismatec SA, Switzerland). The flow rate of receptor fluid 
through the receiver compartment of each diffusion chamber was controlled at 4 mL/h. Test 
compounds were added to the donor side of the chamber, and sequential samples were collected 
from the receiver side at predetermined times over a period of 4 h. Donor compartments of 
diffusion chambers were capped directly after adding test solutions. A constant temperature was 
maintained by circulating 37 °C water through the diffusion chambers holder. 
Transport studies 
The flow-through system was used to determine the rate of permeation of selective 
substrates for OCTs and OATs across the BME-UV monolayer. To characterise the role of 
transporters in the substrates' permeation across the monolayer, rates were compared from the 
apical to the basolateral side and vice versa, in the presence and absence of selective transporter 
inhibitors and over a wide range of concentrations. In the case of carrier mediated transport, the 
permeation rate constant is expected to be dependent on the direction of the substrate movement 
across the mammary epithelial cells [apical-to-basolateral (Ap-to-BL) or basal-to-apical (BL-to-
Ap)] and concentration (saturable at higher level) and to decrease significantly in the presence of 
selective inhibitors. 
Test compounds were prepared in both TBM and ApM together with mannitol as a cell 
monolayer integrity marker (Kimura et al., 2006). The transport experiment was initiated by 
adding 1.5 mL of test solutions containing 100 μm of either [14C]-tetraethylammonium bromide, 
a known selective substrate for OCT (Goralski et al., 2002; Goralski and Sitar, 1999; Kimura et 
al., 2006; Schomig et al., 1993) or [3H]-estrone sulfate, a known selective substrate for OAT 
(Dantzler and Wright, 2003; Kusuhara et al., 1999; Sai and Tsuji, 2004; Takeda et al., 2001) to 
the upper compartment (donor) together with 2 μm of [3H]- or [14C]-mannitol (Mnt) depending 
on the radiolabelled test compound that was used in the experiment. Mannitol was used as a 
marker for paracellular movement to monitor the integrity of the mammary epithelial monolayer 
as it is hydrophilic and relatively small molecule (mol. wt 182) (Kimura et al., 2006). 
To test, if the permeability of the selective substrates was dependent on direction, the cell 
monolayer was mounted with either the apical or the basolateral side facing the donor 
compartment. Each of the 14 diffusion chambers was randomly assigned to a direction. 
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If directionality was observed in the permeation rate constant, the involvement of 
transporters was confirmed by examining the effect of an inhibitor of OCT (cyanine) (Goralski et 
al., 2002; Schomig et al., 1993) and an inhibitor of OAT (probenecid) (Lash et al., 2007; Takeda 
et al., 2001) on the permeation rate constants of tetraethylammonium (TEA) and estrone sulfate 
(EsS) in both directions. Finally, if the effect of inhibitors was found to be significant, then 
permeation rate constants for both TEA and EsS were determined for a range of concentrations. 
Three replicates were performed for each treatment in the above experiments. Two 
control diffusion chambers with only the permeable support as a separator between the donor and 
receiver compartments were also included in each experiment. Sequential samples of the 
receptor fluid were collected at 15-min intervals for the first hour, 30-min intervals for the next 
2 h and finally at the fourth-hour of the experiment. At the end of the fourth hour, the residual 
media in the diffusion chambers were aspirated. 
Sample analysis 
Substrate concentrations were measured in both the donor and acceptor media for each 
sampling time. One millilitre of sample was transferred into a glass scintillation vial and 0.3 mL 
of 30% H2O2 added for decolorization purposes. After incubating the sample at 55 °C for 1 h, the 
sample was cooled to room temperature and 15 mL of liquid scintillation cocktail (Bioscint®) 
were added. To determine the intracellular content of radioactive isotopes, BME-UV cells were 
lysed by incubating them with 1 ml of Biosol® at 55 °C for 2 h. Fifteen millilitre of liquid 
scintillation cocktail (Bioscint®) were then added to the lysed cells after the samples cooled to 
room temperature. Samples of either [14C]- or [3H]-radiolabelled test compounds and mannitol 
were assayed by dual labelled β-scintillation counting with quench correction (Beckman 
LS6500; Beckman Coulter, Inc., CA, USA). Automatic calculation of disintegrations per minute 
was used for each sample. 
Data analysis 
The permeation rate constant (Papp, cm/s) of each test compound and mannitol was 
calculated using the following equation (Yamashita et al., 2000):              
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where (dX)/(dt) (μmol/s) is the slope of the graph obtained by plotting the cumulative amount of 
the test compound in the receiver compartment vs. time. The slope was measured between time 
points at which the system was judged to be at pseudo-equilibrium as evidenced by the slope 
forming a straight line on a linear scale. It can be accepted that sink conditions were maintained 
throughout the experiment as <10% of the test compound deposited in the donor compartment 
appeared in receiver compartment and the test compound was continuously removed from the 
receiver compartment by receptor fluid flow. A (cm2) is the effective diffusion area of the cell 
culture insert and C0 (μm) is the compound's initial concentration in the donor compartment. 
Statistical analysis 
All statistical analyses were performed using the commercially available software 
sigmastat® (Systat Software Inc., San Jose, CA, USA). Group comparisons were made by 
repeated measures analysis of variance (ANOVA), followed by Tukey's test when anova showed 
significant differences among treatments to determine the specific pairs of treatments between 
which statistically significant differences occurred. Comparison between control and other 
treatments was made by Student's t-test. The level of significance for all tests was set at P < 0.05. 
  Results 
Barrier function of the BME-UV monolayer 
The permeation rate constant for both TEA (161 × 10−6 cm/s) and EsS (122 × 10−6 cm/s) 
in the control diffusion chambers that had only a permeable support was at least 30 and 80 times 
greater than BL-to-Ap and Ap-to-BL permeation rate constants respectively of either test 
compounds in the diffusion chambers with the monolayer of BME-UV cells as a separator 
between donor and receiver compartments. In addition, the permeation rate constant of mannitol 
across monolayer of BME-UV cells was 0.91 ± 0.4 × 10−6 cm/s. These results indicate that the 
monolayer of BME-UV cells forms an effective barrier to the movement of these compounds. 
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Transport study 
The cumulative concentrations of TEA and EsS in the receiver compartment as a function 
of time in the absence or presence of inhibitors are shown in Figs 3-1 & 3-2 respectively. The 
permeation rate constants of TEA and EsS across BME-UV monolayer under different 
conditions are summarized in Table 1. Transport of TEA in the BL-to-Ap direction was 
significantly greater by a factor of 2.6 than that in the Ap-to-BL direction (Table 1). Similar 
directionality was also observed in the EsS transport experiment (the BL-to-Ap permeation rate 
constant was 3.3 times greater than in the other direction). The permeation rate constants for 
TEA were three and two times greater than for EsS in the Ap-to-BL and BL-to-Ap directions 
respectively. 
The permeation rate constant of TEA was decreased significantly by increasing the initial 
concentration of TEA in the donor compartment from 100 to 500 μm and then to 1000 μm (Fig. 
3-3). While for EsS, it was decreased significantly only when the initial concentration of EsS 
was increased in the donor compartment from 100 to 500 μm. When the concentration was 
increased from 500 to 1000 μm, there was no significant difference in the permeation rate 
constant (Fig.3-4). 
Inhibition study 
The permeation rate constant of TEA was decreased significantly (approximately 49%) 
only in the BL-to-Ap direction by adding cyanine (OCT-inhibitor) to the donor compartment 
(Table 3-1). The permeation rate constant of TEA was not changed significantly by adding 
probenecid (OAT-inhibitor) to the donor compartment in either direction (data not shown). 
Similar results, but not identical were found for EsS in which the permeation rate constant was 
decreased significantly (approximately 36%) only in the BL-to-Ap direction by adding 
probenecid (OAT-inhibitor) to the donor compartment (Table 3-1). The permeation rate constant 
of EsS was not changed significantly by adding cyanine (OCT-inhibitor) to the donor 
compartment in either direction (data not shown). 
Discussion 
The immortalised bovine mammary epithelial cell line (BME-UV) that was used for the 
present study was selected for its ability to establish a cell polarity and form tight junctions 
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between adjacent cells when grown as a monolayer on a filter support that acts as a barrier 
between dissimilar fluid compartments (Schmidt et al., 2001). Accepted criteria for monitoring 
the quality of monolayers in transport studies include transepithelial electrical resistance (Rte), 
and permeability to hydrophilic markers like mannitol. The diffusion of mannitol across the 
epithelial monolayers is limited to the paracellular route (Shaw, 1996). In the present study, the 
Papp of mannitol (0.91 ± 0.4 × 10−6 cm/s) across monolayer of BME-UV cells was comparable 
with those obtained in mouse mammary epithelial monolayer (1.94 × 10−6 cm/s) (Toddywalla et 
al., 1997) and in human mammary epithelial monolayer (2.6 × 10−6 cm/s) (Kimura et al., 2006), 
indicating that the monolayer of BME-UV cells is tight enough to evaluate transcellular drug 
transport. 
The Bronaugh-type flow-through diffusion cell system that was used in this study has 
numerous advantages. The system allows for automatic sampling of receiver fluid to accurately 
monitor the absorption/time profile. Multiple replicates of treatment conditions could be obtained 
cost-effectively. In addition, the permeability to a test compound in two directions, from the Ap-
to-BL and BL-to-Ap directions and both passive and active transport processes could be studied. 
Most importantly, receiver fluid flow maintained effective infinite sink conditions in the receiver 
compartment throughout the experiment, which reduces the effect of test compound molecules 
diffusing back from the basolateral to the apical side or vice versa, thereby isolating directional 
processes of drug movement across the epithelial barrier (Bronaugh and Stewart, 1985). 
The directionality of both TEA and EsS transport suggests the functional expression of 
OCT and OAT, respectively, in the BME-UV cells. A similar polarised transport process for 
TEA has been identified previously in human mammary epithelial monolayers and attributed to 
the human OCT (Kimura et al., 2006). Several in vivo studies have also suggested that organic 
anions (N4-acetylated P-aminohippuric acid, N4-acetylated sulfanilamide and nitrofurantoin) are 
actively transported across the bovine, caprine and rat mammary epithelium into milk, 
respectively, as their observed milk/plasma ratio was 3–30 times higher than the predicted value 
which calculated based on the pKa of drug and the pH of both milk and plasma (Kari et al., 
1997; Rasmussen, 1969a, b). Other studies confirmed the presence of a cimetidine transport 
system in the rat mammary epithelium that is saturable and inhibited by ranitidine (McNamara et 
al., 1996). 
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Decreasing values of the permeation rate constant with increasing concentrations being 
added to the donor compartment serves as further evidence for the involvement of carrier 
mediated transport in the movement of TEA and EsS across the BME-UV monolayer. This is 
because saturation of the carriers at higher concentrations leads to the rate of movement no 
longer being proportional to the concentration gradient. The permeation rate therefore decreases 
as it is normalised to the concentration gradient. The permeation rate constant of TEA decreased 
significantly when initial concentrations were increased from 100 to 500 μm and then 1000 μm, 
suggesting that the carriers were saturated at these high concentrations. Increasing the initial 
concentration of EsS from 100 to 500 μm also decreased the permeation rate. However, an 
increase from 500 to 1000 μm in the donor compartment had no effect on the permeation rate 
constant of EsS, This may explained by a significant contribution of passive diffusion to the 
movement of EsS across the monolayer of BME-UV cells. The same conclusion was also found 
by (Koljonen et al., 2008) and (Neuhoff et al., 2005) who studied passive and active transport 
mechanisms of acidic drugs across Caco-2 cells. 
The significant decrease in the permeation rate constant of both TEA and EsS in the BL-
to-Ap direction after adding OCT and OAT inhibitors, respectively, also supports the hypothesis 
that the directional movement of organic cations and anions across the BME-UV monolayer is 
mediated by transporters. As the test compounds crossed the monolayer in the presence of 
inhibitors, albeit at a significantly lower rate, passive diffusion may play a role in the movement 
of these compounds across the mammary epithelium. Further studies are needed to determine the 
concentrations of inhibitors that are required to saturate the transporters.  
This is the first report of the presence of carrier-mediated directional transport in 
functionally differentiated bovine mammary epithelial monolayers. The BME-UV monolayer 
appeared to be more permeable to TEA compared with EsS, as evidenced by a lower value for 
Papp for the latter. This could be explained by differences in the number of organic cation and 
anion transporters per BME-UV cell. It may also be explained by the differences in the 
physicochemical properties of these compounds and their affinity to the transporters that are 
present in the BME-UV cells. 
Transporters play a key role in governing bodily drug absorption, distribution and 
elimination. They also play a role in drug–drug interactions and interindividual differences in 
pharmacokinetic profiles (Ito et al., 2005). Knowledge of transporter expression in the mammary 
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epithelium and their apical or basolateral directionality is therefore a necessary step to study the 
mechanisms that result in xenobiotic residues in milk. This is an important concern to the 
scientists in both pharmaceutical industry and public health field. 
A better understanding of the mechanisms that contribute to the movement of xenobiotics 
across the mammary epithelium would enhance our ability to predict milk xenobiotic 
concentrations at specific times following drug administration, or after accidental exposure to 
environmental contaminants, such as mycotoxins, pesticides and toxic metals. The effect of 
drug–drug interactions and changes in milk composition could also be explored. Milk loss could 
thereby be minimised by determining the exact amount of milk that should be discarded based on 
early information about the transport characteristics of potential xenobiotics into milk. Specific 
transporters responsible for the excretion of these xenobiotics into milk could also be blocked. 
The expression of members of the OCT and OAT families on the membrane of the BME-
UV cells may relate to a physiological role of these transporters in milk production. Conversely, 
they may impart a protective role to the lactating mammary gland extruding potentially toxic 
xenobiotics into milk. But this increases the risk of milk residues that are potentially harmful to 
suckling off-spring or the human consumer. The potential involvement of drug efflux 
transporters, such as P-glycoprotein and multidrug resistance associated protein, on the 
monolayer of BME-UV cells remains unknown and further studies should be performed. Further 
studies are also required to quantify the activity of these transporters and determine the substrate 
concentrations that lead to saturation. 
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Figures and tables 
Table 3-1.The permeation rate constants (Papp) for model substrates across monolayer of BME-
UV cells or support alone from apical-to-basolateral (Ap-to-BL) or BL-to-Ap directions in the 
absence or presence of inhibitors (Api-to-BL) and (BLi-to-Ap).  
 Papp ± SD (x 10-6 cm/s) 
 Ap-to-BL¥ Api-to-BL¥ BL-to-Ap¥ BLi-to-Ap¥ Support 
TEA 2.0 ± .02 1.9 ± .06 5.1 ± .4* 2.6 ± .2** 161 ± 18*** 
EsS 0.66 ± .06 0.62 ± .07 2.2 ± .1ж 1.4 ± .08 ж ж 122 ± 34 ж ж ж 
Different numbers of stars & daggers indicate the permeation rate constants are significantly 
different (P < 0.05).                                                                                                                                
‡indicates Ap-to-BL: apical to basolateral and BL-to-Ap: basal to apical directions in the absence 
or presence of inhibitors (Api-to-BL) and (BLi-to-Ap). 
 
 
 
Figure 3-1. In vitro cumulative concentration–time profiles of tetraethylammonium (TEA).   
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Permeation of TEA across monolayer of BME-UV cells from apical-to-basolateral (Ap-
TEA) and BL-to-Ap (BL-TEA) directions in the presence or absence of inhibitors (Ap-
(+Cyn)) and (BL-(+Cyn)). Data represent mean ± SD of three replicates. 
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Figure 3-2. In vitro cumulative concentration–time profiles of estrone sulphate (EsS). 
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Figure 3-3. Permeation rate constant of tetraethylammonium across monolayer of BME-UV cells 
from BL-to-Ap (BL) direction.  
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Data represent mean ± SD of three replicates. Different number  
Permeation of EsS across monolayer of BME-UV cells from apical-to-basolateral (Ap-
EsS) and BL-to-Ap (BL-EsS) directions in the presence or absence of inhibitors (Ap-
(+Prob)) and (BL-(+Prob)). Data represent mean ± SD of three replicates. 
 
of stars indicates the permeation rate constants are significantly different (P < 0.05). 
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Figure 3-4. Permeation rate constant of estrone sulphate across monolayer of BME-UV cells 
from BL-to-Ap direction.  
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Data represent mean ± SD of three replicates. Different number  
of stars indicates the permeation rate constants are significantly different (P < 0.05). 
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CHAPTER 4 - MOLECULAR AND FUNCTIONAL 
IDENTIFICATION OF ORGANIC ANION TRANSPORTER 
ISOFORMS IN CULTURED BOVINE MAMMARY EPITHELIAL 
CELLS (BME-UV) 
Submitted to Journal of Veterinary Pharmacology and Therapeutics (September 2010). 
Abstract 
Mammary epithelial cells express a diversity of membrane transporters including 
members of organic cation and organic anion (OAT) transporter subfamilies. Four mammal OAT 
isoforms have been identified: OAT-1, OAT-2, OAT-3, and OAT-4. The pharmacological 
significance of OAT isoforms has been emphasized because of their role in the movement of a 
wide variety of substrates across epithelial barriers. The present study identified (molecularly 
and functionally) bOAT isoforms in BME-UV cells. mRNA expression levels of all tested 
transporters in BME-UV cells were less than expression levels of the corresponding transporters 
in bovine kidney. Directionality in the flux of P-aminohippuric acid and acetylsalicylate, 
compounds known to interact with OAT-1 and OAT-2, respectively, across BME-UV 
monolayers was not observed at the concentrations used in this study. Directionality was, 
however, observed in the flux of estrone sulfate. Adding probenecid, penicillin G or non-
radiolabeled estrone sulfate to the apical donor compartment significantly increased the apical to 
basolateral flux of estrone sulfate across the BME-UV monolayer. These results suggest that 
BME-UV cells express an organic anion transport system, making it a potentially useful model 
to study the role of this transport system in the mammary epithelial barrier.   
Introduction 
Numerous compounds, such as drugs, environmental pollutants, and metabolites of both 
exogenous and endogenous origins, exist as organic anions at physiological pH (Miyazaki et al., 
2004). These compounds are transported by the organic anion transporter (OAT) system 
expressed in different epithelial cells, including mammary epithelial cells (Al-Bataineh et al., 
2009; Alcorn et al., 2002; Gilchrist and Alcorn, 2009; Sekine et al., 2006). The OAT subfamily, 
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encoded by the SLC22A, is a group within the organic ion transporter family that includes 
organic cation transporter (OCT), OCT novel type/carnitine, and OAT subfamilies (Koepsell et 
al., 1999; Sekine et al., 1998a; Sekine et al., 1998b; Tamai et al., 1998; Tamai et al., 1997). 
Four mammal OAT isoforms have been identified: OAT-1 (Sekine et al., 1997), OAT-2 
(Sekine et al., 1998a), OAT-3 (Kusuhara et al., 1999), and OAT-4 (Cha et al., 2000). These OAT 
subfamily members differ in substrate selectivity and localization. For instance, OAT-1, OAT-2, 
and OAT-3 are involved in the uptake of various endogenous and exogenous substances via the 
basolateral membrane, whereas OAT-4 is involved in either the uptake or the secretion of 
different substances via the apical membrane (Giacomini et al., 2010; Miyazaki et al., 2004; 
Sekine et al., 2006; Takeda et al., 2001).  
OAT-1 and OAT-3 have distinct substrate selectivity. For example, OAT-1 has a high 
affinity (Km = 14 µM) for the classical renal OAT substrate P-aminohippuric acid (Pah), but 
OAT-3 has no affinity for Pah. In contrast, OAT-3 has a high affinity (Km = 2.3 µM) for estrone 
sulfate (EsS), whereas OAT-1 has only a very slight affinity for EsS (Dantzler and Wright, 2003; 
Sekine et al., 2000). Acetylsalicylate (Sal) is a selective substrate for OAT-2 (Miyazaki et al., 
2004; Sekine et al., 2006), which mediates saturable uptake of Sal when expressed in Xenopus 
laevis oocytes (Sekine et al., 1998a). Also, EsS has been reported to interact, with high affinity, 
with OAT-4 (Sekine et al., 2006). These differences and similarities in substrate affinities make 
it possible to map transporters functionally that are involved in processes across the epithelial 
monolayer. 
The pharmacological significance of OAT isoforms has been emphasized because of their 
role in the movement of a wide variety of substrates across the epithelial barrier including 
clinically important compounds such as loop and thiazide diuretics, nonsteroidal anti-
inflammatory drugs, antiviral agents, environmental pollutants (e.g., the anionic herbicide 2,4-
dichlorophenoxyacetic acid), as well as sulfonamide and β-lactam antibiotics,  (Sekine et al., 
2000; Sweet et al., 2001).  
Different cell culture in vitro models have been established to study drug flux across 
mammary epithelial cells (Kimura et al., 2006; Toddywalla et al., 1997). An immortalized 
bovine mammary epithelial cell line (BME-UV) was used in the present study. This cell line was 
selected as a model for the blood-milk barrier due to its ability to express transport proteins (Al-
Bataineh et al., 2009), establish a cell polarity with well-formed tight junctions between adjacent 
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cells, and exhibit a transepithelial electrical resistance (Quesnell et al., 2007a; Schmidt et al., 
2001). The aim of this study was to identify molecularly and functionally bOAT isoforms in 
BME-UV cells.  
Materials and Methods 
Expression of genes encoding for the different bOAT isoforms in cultured BME-UV cells 
were determined using real time-PCR technique (RT-PCR). Transport studies using compounds 
known to interact with the OAT isoforms were conducted to determine whether the transporters 
were functional and significantly influenced the flux of substances across the epithelial barrier.  
Cell Culture 
The BME-UV cells were cultured under conditions similar to those described previously 
in detail (Quesnell et al., 2007a; Schmidt et al., 2001). Briefly, the BME-UV cells were grown to 
65-75% confluency in 25 cm2 plastic culture flasks (Corning, Inc., Corning, NY). Then, 
dissociated and dispersed cells were seeded on permeable polyester inserts, (Transwell, Corning, 
Inc.,) and fed with asymmetrical media. Typical bovine medium (TBM), which contains little 
lactose and has concentrations of electrolytes that closely mirror serum, bathed the basolateral 
aspect of the cells throughout all experiments. The apical aspect was exposed to apical bovine 
medium (ApM) of low electrolyte-high lactose composition that resembles the ionic composition 
of milk. Composition of TBM and ApM were reported previously (Quesnell et al., 2007a; 
Schmidt et al., 2001). The cells were incubated at 37°C in a humidified atmosphere containing 
5% CO2. Media on both the apical and basolateral aspects of the cells were refreshed daily. Cells 
were maintained in culture on permeable supports for 2 weeks to form a confluent, polarized and 
electrically tight monolayer prior to all experiments. 
Identification of bOAT transporters in BME-UV cells 
  
RT-PCR 
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Expression levels of bOAT isoforms (bOAT-1, bOAT-2, bOAT-3, and bOAT-4) in 
BME-UV cells were determined and compared with expression levels of the corresponding 
transporters in bovine kidney, one of the major routes of organic anion elimination. 
RNA Extraction 
RNA was isolated from confluent monolayers of BME-UV cells and bovine kidney 
lysates using RNeasy Mini kit (QIAGEN, Foster City, California) according to the 
manufacturer’s directions. RNA concentrations were determined by the measurement of optical 
density at 260 nm (NanoDrop 8000, Thermo Scientific, Rockford, IL). Isolated total RNA 
integrity was verified by an OD260/OD280 absorption ratio greater than 1.8 and less than 2.0. Non-
degraded and sufficiently concentrated RNA (~0.5 to 1.0 µg/µl) was used in RT-PCR assays. 
Primer Design for RT-PCR 
Bovine sequences for each gene were obtained from the National Center for 
Biotechnology Information Genebank (http://www.ncbi.nih.gov). Primer pairs for target genes 
(table 4-1) were designed using Primer3 software (http://frodo.wi.mit.edu/primer3/), a web-based 
primer design program. Both primer pairs were custom synthesized by Integrated DNA 
Technologies (Integrated DNA Technologies (http://www.idtdna.com/Home/Home.aspx). 
RT-PCR  
The expression of target bOAT isoforms in mammary epithelial cells was determined by 
RT-PCR (iCycler, Bio-Rad Laboratories, Hercules, CA) with the use of a commercial kit 
(Quantitect SYBR Green RT-PCR kit and reagents, Qiagen). Reactions were performed in a final 
volume of 25 μL containing 100 ng of template RNA, 0.5 μM forward and reverse primers, 0.25 
μL Quantitect RT Mix, 12.5 μL Quantitect SYBR Green (1x) and 8.25 μL RNase-free Water. 
Triplicate determinations were performed for each combination of RNA isolation and target 
sequence in a 96-well optical plate. This experiment was repeated five times (i.e. RNA isolated 
in 5 different occasions from different passage numbers) with RT-PCR conducted on separate 
days. RT-PCR assay was conducted in the manner where samples of bovine kidney, no-template 
reaction and no reverse transcriptase were included in the assay.  
 34 
RT-PCR Protocol 
The RT-PCR protocol consisted of reverse transcription (50°C for 30 minutes), PCR 
initial activation (95°C for 15 minutes), followed by 40 cycles of denaturing at 94°C for 15s, 
annealing at 58°C for 30s, and extension at 72°C for 30s. A melt curve analysis from 65°C-95°C 
at 0.5°C/s was conducted immediately following PCR. Relative gene expression in different 
treatments to the average untreated was calculated using 2-∆∆CT method according to Livak and 
Schmittgen (2001).  
Transport studies 
To study the function of bOAT members in the BME-UV monolayer, we compared the 
flux of different anionic compounds known to interact with bOAT isoforms from apical-to-
basolateral (Ap-to-BL) side and vice versa in the presence and absence of other compounds 
known to interact with different drug transporters including bOAT. Test compounds were 
prepared in TBM or ApM together with 3H-mannitol (3H-Mnt). Because Mnt is a hydrophilic 
and relatively small molecule (mol. wt. 182), it was used as a marker for paracellular movement 
to monitor the integrity of the mammary epithelial monolayer (Kimura et al., 2006).  
Flow-Through Diffusion Cell System 
Confluent monolayers of BME-UV cells on permeable supports were mounted as a 
barrier in a flow-through diffusion cell system (Permegear, Bethlehem, PA). The system has 
automated receptor fluid collection and a high precision multichannel dispenser (Ismatec SA, 
Switzerland). The flow rate of receptor fluid through the receiver compartment of each diffusion 
chamber was controlled at 4 ml/h.  Temperature was maintained at 37°C by circulating water 
through the diffusion chambers’ holders. Donor compartments of diffusion chambers were 
capped directly after adding test solutions. Sequential samples were collected from the receiver 
side at regular intervals (15 min) over a period of 120 min. Samples of either [14C]- or [3H]-
radiolabeled test compounds were assayed by dual labeled β-scintillation counting with quench 
correction (Beckman LS6500, Beckman Coulter, Inc., CA). Automatic calculation of 
disintegrations per minute (DPM) was used for each sample.  
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bOAT-1 
The flux of 2.0 µM P-aminohippuric acid ([14C]-Pah), a compound known to interact 
with OAT-1 (Sekine et al., 2006), together with 0.025 µM [3H]-Mnt was studied across the 
BME-UV monolayer from Ap-to-BL side and vice versa in the presence and absence of 
probenecid (1 mM), a compound known to interact with OATs (Lash et al., 2007), Verapamil 
(50 µM), a compound known to interact with P-glycoprotein (Kim, 2002), and  EsS (100 µM), a 
compound known to interact with OAT-3 (Dantzler and Wright, 2003). These compounds were 
added separately into the donor compartment together with Pah at the start of each experiment. 
bOAT-2 
The flux of acetylsalicylate (Sal), a compound known to interact with OAT-2 (Miyazaki 
et al., 2004; Sekine et al., 2006) was studied across the BME-UV monolayer from Ap-to-BL side 
and vice versa in the presence and absence of probenecid (1 mM). The transport experiment was 
initiated by adding 1 ml of test solution containing 1.0 µM [14C]-Sal together with 0.025 µM 
[3H]-Mnt into the donor compartment. 
bOAT-4 
The flux of EsS, a compound that has been reported to interact with OAT-4 with high 
affinity (Sai and Tsuji, 2004; Sekine et al., 2006; Takeda et al., 2002), was studied across the 
BME-UV monolayer in both directions (Ap-to-BL and BL-to-Ap). The transport experiment was 
initiated by adding 1 mL of test solution containing 0.02 µM [3H]-EsS together with 2 µM [14C]-
Mnt to the donor compartment. Moreover, the Ap-to-BL flux of [3H]-EsS across the BME-UV 
monolayer was determined in the presence and absence of 1 mM probenecid, 100 µM PenG, and 
20 µM of non-radiolabeled EsS. These compounds were added separately into the donor 
compartment together with EsS.  
Data Analysis  
The flux (µmol/cm2 per hour) of both tested compound and mannitol were calculated 
based on the amounts of compound recovered in the receiver compartment per unit time and then 
were normalized by the effective diffusion area (cm2) of the cell culture insert.  Then, the flux of 
tested compound was divided by mannitol flux at each measured time point to account for 
changes in overall epithelial integrity.  
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Statistical Analysis  
All statistical analyses were performed using the commercially available software 
SIGMASTAT (Systat Software Inc., San Jose, CA). Group comparisons were made by repeated 
measures ANOVA. When the ANOVA showed significant differences among treatments, the 
Holm-Sidak posttest was performed to determine the specific pairs of treatments between which 
statistically significant differences occurred. The level of significance for all tests was set at P < 
0.05. 
Results 
mRNA expression of bOAT isoforms in BME-UV cells 
Expression levels of all tested transporters in BME-UV cells were less than expression 
levels of the corresponding transporters in bovine kidney by at least 2 orders of magnitude 
(Table 4-2). The relative expression of bOAT-4 in BME-UV cells to that in bovine kidney was 
the highest among tested bOAT isoforms (bOAT-4: 3.1 ± 0.7 x 10-2 fold; n = 5). 
Transport studies of organic anion compounds across BME-UV monolayers 
 The Mnt-normalized flux of Pah across the BME-UV monolayer in the Ap-to-BL 
direction was not significantly different from the Pah flux in the opposite direction (BL-to-Ap) at 
the concentration used in the current study (Fig. 4-1). Adding probenecid or verapamil together 
with Pah to the apical donor compartment had no distinguishable effect on the Ap-to-BL flux of 
Pah. The same results were observed in the Pah flux in the opposite direction (BL-to-Ap) after 
adding probenecid or EsS together with Pah to the basolateral donor compartment.  
 Directionality in the Mnt-normalized flux of Sal across the BME-UV monolayer was not 
observed at the concentration used in the current study (Fig. 4-2). Furthermore, adding 
probenecid together with Sal to the donor compartment had no distinguishable effect on the Sal 
flux in either direction.  
 The Mnt-normalized flux of EsS across the BME-UV monolayer from BL-to-Ap 
direction was more than 2 times the flux in the opposite direction (Fig. 4-3). The Ap-to-BL flux 
of EsS across the BME-UV monolayer was significantly increased by adding probenecid 
together with EsS to the apical donor compartment (Fig. 4-4). Adding PenG also increased the 
Ap-to-BL flux of EsS but to a lesser degree than when probenecid was added. The maximum 
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increase in the Ap-to-BL flux of EsS was observed after adding non-radiolabeled EsS together 
with [3H]-EsS to the donor compartment. 
The amount of EsS that crossed BME-UV monolayers in the presence of probenecid, 
PenG or non-radiolabeled EsS was significantly higher than the amount of EsS that crossed the 
BME-UV monolayer when [3H]-EsS was added alone to the apical donor compartment. The 
highest amount value (5.4 ± 0.1 x10-3 nmol) was when non-radiolabeled EsS was added together 
with [3H]-EsS to the donor compartment, which was double the amount value of EsS that crossed 
BME-UV monolayer when [3H]-EsS was added alone. Furthermore, the detected intracellular 
content of EsS, when probenecid, PenG or non-radiolabeled EsS were added together with [3H]-
EsS to the apical donor compartment, was higher than when EsS was added alone. The recovery 
of EsS from the entire system at the conclusion of experiment was 93 ± 2 %. 
Discussion 
The expression levels of all tested transporters in BME-UV cells were less than the 
expression levels of the corresponding transporters in bovine kidney, one of the major routes of 
organic anion elimination (You, 2002). The fluxes of either Pah or Sal across the BME-UV 
monolayer are similar in both directions (Ap-to-BL or BL-to-Ap) at the concentrations used in 
this study. Directionality was, however, observed in the flux of EsS across the BME-UV 
monolayer, this could be attributed to the involvement of the organic anion transport system in 
the molecules’ passage across BME-UV cells.  
EsS is a substrate for both OAT-3 and OAT-4. Both of these transporters were expressed 
in BME-UV cells, with bOAT-4 having the highest relative expression compared to the kidney, 
where it plays an important role in the excretion of anionic substances. In a previous study (Al-
Bataineh et al., 2009), we elucidated the involvement of a carrier-mediated transport system in 
the passage of EsS across the BME-UV monolayer in the BL-to-Ap direction that was inhibited 
by probenecid and became saturated at higher concentration.  
The excretion of EsS across the apical membrane may involve more than one transport 
system as demonstrated by the differences in the increase in the EsS flux when probenecid and 
non-radiolabeled EsS were added. Probenecid is a compound known to interact with OAT, while 
non-radiolabeled EsS may interact with bOAT as well as other transporters including BCRP and 
this may explain the higher EsS flux after adding non-radiolabeled EsS than after adding 
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probenecid to the donor compartment. Probenecid, PenG and non-radiolabeled-EsS increased the 
Ap-to-BL flux of EsS by either competing with EsS or inhibiting directly the transporters that 
involved in EsS flux. The concentration of 0.02 µM EsS was selected because it is well below 
the Km value of EsS when it is up taken by OAT-4 that expressed in Xenopus laevis oocytes 
(Km = 1 µM) (Cha et al., 2001). 
Pah and Sal were added to the donor compartment at concentrations of 2 µM and 1 µM, 
respectively, which are well below the Km values of both compounds (Km = 14.3 µM, and 89 
µM, respectively) as determined by uptake into OAT expressing Xenopus laevis oocytes (Sekine 
et al., 1998a; Sekine et al., 1997). The absence of directionality in the flux of either test 
compounds might be explained by low expression of the transporters for these compounds in 
BME-UV cells. This conclusion is further supported by the unchanged flux of Pah and Sal when 
other anionic compounds (e.g. probenecid) known to interact with OAT were added to the donor 
compartment. The observed flux of both Pah and Sal across the BME-UV monolayer is therefore 
most likely attributed to saturated transporters-mediated processes with the possible addition of 
some passive diffusion. Studies with a range of concentrations would be needed to confirm this 
hypothesis.  
Results from the transport studies reported in this manuscript are consistent with low 
observed mRNA expression of bOAT in BME-UV cells as well as with observations reported 
from other species (Alcorn et al., 2002; Gerk et al., 2001b). OAT-1 and bOAT-2 were not 
detected in human mammary epithelial cells purified from pooled fresh breast milk samples 
(Alcorn et al., 2002), or lactating rat mammary tissue (Gerk et al., 2001b). These authors did not 
detect OAT-3 and OAT-4 either, although we did detect relatively higher bOAT-4 expression. 
The most likely explanation for this disagreement is experimental method. We used cell culture 
(higher amount of mRNA), while tissue and collected cells in milk samples may have yielded 
less mRNA and was therefore less sensitive. Another reason is species differences in OAT 
expression (Buist and Klaassen, 2004).  
The flux of different anionic compounds known to interact with OAT in our in vitro cell 
culture model (BME-UV) is consistent with other observations reported in lactating cows and 
other species such as goat, mouse and rat. Earlier in vivo studies in lactating cows and rats 
showed that experimental and theoretical (calculated on the basis of pH partition concept) milk-
to-plasma ultra-filtrate ratios were in close agreement for Pah and Sal and not altered by drug 
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concentrations or probenecid (Gerk et al., 2001a; Miller et al., 1967). Thus, a passive diffusion 
process may govern the movement of both Pah and Sal from plasma to milk.  
The milk concentration of endogenous EsS and EsS infused close-arterially into the 
mammary gland in bovine and a non-pregnant goat, respectively, was significantly greater than 
that in plasma, indicating that EsS was actively transferred from blood to milk against a 
concentration gradient (i.e. EsS cross mammary epithelial barrier by a carrier mediated process) 
(Heap et al., 1983, 1984).  
In summary, the results from the current study indicate that EsS flux across BME-UV 
cells is transporter-mediated. The transporter that most likely plays a role in this flux is bOAT-4, 
due to its relatively higher expression compared to other members of this transporter family. 
bOAT-3 and other transporters such as BCRB may also play a role in EsS flux across the BME-
UV cells. Though, the relative importance of the different bOAT isoforms in the milk excretion 
of compounds in vivo remains unknown and will require further studies. The expression of 
organic anion transport system in mammary epithelial cells has important implications for 
understanding the barrier function of the mammary epithelium and provides insight into the role 
of bOAT system in the accumulation and/or removal of anionic molecules from milk and/or 
plasma.  
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Figure and Tables 
Table 4-1. Primer sequences and amplicon size (base pairs) for each transporter gene and 
GAPDH gene. 
Transporter 
gene 
Forward primer Reversed primer 
Amplicon 
size 
bOAT-1 GGTGTACCCCACAATGATCC CCACGTCTTGCACTGTGTCT 218 
bOAT-2 CCCTGAACAAAGTAGCTGCC CACCGACAGATAGACCAGCA 239 
bOAT-3 ATTTGATGACCCTGAGGACG GTGTCTCAGGCAGGAAGAGG 270 
bOAT-4 CACCTCCACCATTGTGACTG TGTAACCCTAGCCCCAGATG 194 
bGAPDH AAGATTGTCAGCAATGCC ACAGACACGTTGGGAG 297 
 
 
 
 
Table 4-2. Relative expression of mRNA coding for bOATs in BME-UV cells compared to the 
expression of the corresponding transporters in bovine kidney. Data represent mean ± SE of five 
replicates. 
 Transporter  
 OAT-1 OAT-2 OAT-3 OAT-4 
mRNA expression1 9.2E-04 33E-04 7E-04 310E-04 
SEM2 4.5E-04 14E-04 2E-04 70E-04 
1 Expression of mRNA transporter in BME-UV cells relative to mRNA expression in bovine 
kidney. 
2SEM: standard error of the mean. 
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Figure 4-1. Flux of Pah across the BME-UV monolayer in both directions; apical to basolateral 
(Ap) and basolateral to apical (BL) side. 
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Figure 4-2. Flux of Sal across the BME-UV monolayer in both directions; apical to basolateral 
(Ap) and basolateral to apical (BL) side. 
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No directionality is observed in the mannitol-normalized flux of P-aminohippuric acid (Pah) 
across BME-UV monolayers. Pah (2.0 µM) flux across the BME-UV monolayer from apical 
to basolateral side (Ap) and from basolateral to apical side (BL) in the presence and absence 
of probenecid (+Prob), verapamil (+Verp), and estrone sulfate (+EsS). Data represent mean ± 
SE of three replicates. 
No directionality observed in the mannitol-normalized flux of Acetylsalicylate (Sal) across 
the BME-UV monolayer. Sal (1.0 µM) flux across the BME-UV monolayer from the apical 
to the basolateral side (Ap) and from the basolateral to the apical side (BL) in the presence 
and absence of probenecid (+Prob). Data represent mean ± SE of three replicates. 
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Figure 4-3. BL-to-Ap flux of EsS across the BME-UV monolayer.  
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Figure 4-4. Flux of EsS across the BME-UV monolayer in both directions; apical to basolateral 
(Ap) and basolateral to apical (BL) side. 
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BL-to-Ap flux of EsS across the BME-UV monolayer was significantly higher than EsS flux in the 
opposite direction (Ap-to-BL) (P < 0.05). Mannitol-normalized flux of 0.02 µM EsS across the BME-
UV monolayer from apical to basolateral side (Ap), and from the basolateral to the apical side (BL). 
Data represent mean ± SE of three replicates. 
 
Probenecid, penicillin G, and non-radiolabeled estrone sulfate (EsS) significantly (P < 0.05) 
increased [3H]-EsS flux across the BME-UV monolayer. Mannitol-normalized flux of 0.02 
µM [3H]-EsS across the BME-UV monolayer from apical to basolateral side (Ap) in the 
presence and absence of probenecid (+Prob), penicillin G (+PenG), and non-radiolabeled EsS 
(+EsS). Data represent mean ± SE of three replicates. 
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CHAPTER 5 - TUMOR NECROSIS FACTOR ALPHA 
INCREASES P-GLYCOPROTEIN EXPRESSION IN A BME-UV 
IN VITRO MODEL OF MAMMARY EPITHELIAL CELLS 
Submitted to Biopharmaceutics & Drug Disposition (July 2010). 
Abstract 
P-glycoprotein is an efflux pump belonging to the ATP-binding cassette super-family that 
influences the bioavailability and disposition of many drugs. Mammary epithelial cells express 
various drug transporters including P-glycoprotein, albeit at low level during lactation. During 
inflammatory reactions, which can be associated with changes in epithelial barrier functions, pro-
inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) are elevated in milk and 
serum. In this study, the role of TNF-α in the regulation of P-glycoprotein was determined in 
cultured BME-UV cells, an immortalized bovine mammary epithelial cell line. The protein 
production of P-glycoprotein and mRNA expression of bABCB1, the gene encoding bovine P-
glycoprotein, were increased after 24 hours of TNF-α exposure. The highest observed effects for 
TNF-α on the regulation of P-glycoprotein was after 72 hours of exposure. Protein and mRNA 
expression remained elevated after 120 hours of TNF-α exposure, but it was lower than the level 
that observed in the cells exposed to TNF-α for 72 hours. The apical to basolateral flux of 
digoxin was decreased in the TNF-α-exposed epithelium. This effect was reversed when 
verapamil or ketoconazole, compounds known to interact with P-glycoprotein, were added 
together with digoxin into the donor compartment. Probenecid, a compound known to interact 
with organic anion transporters, but not P-glycoprotein, did not increase the flux of digoxin. This 
model has important implications for understanding the barrier function of the mammary 
epithelium and provides insight into the role of P-glycoprotein in the accumulation and/or 
removal of specific substrates from milk and/or plasma. 
Introduction 
The body of complex animals is separated into different compartments by biological 
barriers that control the contents of these compartments by including or excluding substances. 
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The functional concept of biological barriers has shifted from that of a static barrier to a complex 
of transport systems that include various efflux pumps. Efflux transporters are a family of ATP-
dependent transport proteins that are known to be present within several major physiological 
barriers including the blood-brain barrier (BBB), kidney, intestine, and placenta (Alcorn et al., 
2002; Madlova et al., 2009; Schrickx and Fink-Gremmels, 2007).  The mammary epithelium, the 
most likely rate-limiting barrier between plasma and milk, expresses various drug transporters 
including P-glycoprotein (Al-Bataineh et al., 2009; Alcorn et al., 2002; Gilchrist and Alcorn, 
2009).  
P-glycoprotein (the ABCB1 gene product, which was formally known as MDR1) is an 
ATP-hydrolyzing efflux pump belonging to the ATP binding cassette super-family (ABC family) 
(Kim, 2002; Mealey, 2004). P-glycoprotein plays an important role in xenobiotic absorption, 
distribution, and elimination as a result of its tissue distribution and cellular localization. For 
example, P-glycoprotein is expressed at the brush borders of epithelial cells in the intestinal tract, 
limiting absorption after oral administration and facilitating secretion into the intestinal lumen 
(Thiebaut et al., 1987). In the liver, P-glycoprotein is expressed at the canalicular (apical) surface 
of hepatocytes, facilitating the excretion of drug molecules, toxins and their metabolites into the 
bile (Chandra and Brouwer, 2004). In the kidney, P-glycoprotein is expressed on the apical 
surface of epithelial cells lining the proximal tubules where it mediates the elimination of 
endogenous metabolic waste products and xenobiotic metabolites (Masereeuw et al., 2003). At 
biological barriers such as the BBB, P-glycoprotein is expressed on the luminal plasma 
membrane of the capillary endothelium, where it prevents the passage of drugs and toxins across 
the capillary endothelium into the brain (Fricker and Miller, 2004).  
P-glycoprotein expression can be modulated by different factors, including drugs, toxic 
agents, heat shock, inflammation, pregnancy and lactation (Alcorn et al., 2002; Sukhai and 
Piquette-Miller, 2000; Sukhai et al., 2000). Several in vitro and in vivo investigations have 
shown that inflammation and pro-inflammatory cytokines such as TNF-α alter the expression of 
P-glycoprotein. The effects of these cytokines appear at different levels of regulation including 
transcriptional, translational, and /or post-translational level (Englund et al., 2007; Sukhai et al., 
2000; Theron et al., 2003).  
During inflammatory reactions, which can be associated with changes in mammary 
epithelial barrier functions, pro-inflammatory cytokines such as TNF-α are elevated in serum and 
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milk. TNF-α is significantly increased in milk and serum in coliform mastitis and Escherichia 
coli-derived lipopolysaccharide-infused mammary gland (Hoeben et al., 2000; Nakajima et al., 
1997; Persson Waller et al., 2003). Furthermore, exposure of bovine peripheral blood 
mononuclear cells to Staphylococcal aureus enterotoxins for 3 hours resulted in the rapid 
production of TNF-α that reached maximal levels by 48 hours then slowly declined by 96 hours 
after stimulation (Yokomizo et al., 1995). The influence of the pro-inflammatory cytokine TNF-
α on the regulation of efflux pump in the mammary epithelial cells has not yet been reported.  
Whole-animal models used to study the effects of pro-inflammatory cytokines on the 
expression and activity of P-glycoprotein provide information on the overall effects of 
inflammation on the regulation of P-glycoprotein. However, the effects of specific cytokines on 
the regulation of P-glycoprotein are complicated by the release of a complex series of 
endogenous cytokines. Thus, tractable in vitro models provide answers to elucidate the specific 
roles of inflammatory modulators. An immortalized bovine mammary epithelial cell line (BME-
UV) was used in the present study. This cell line was selected as a model for the blood-milk 
barrier due to its ability to express transport proteins (Al-Bataineh et al., 2009), establish a cell 
polarity with well-formed tight junctions between adjacent cells, exhibit a transepithelial 
electrical resistance, and its responsiveness to steroid hormones (Quesnell et al., 2007a; Schmidt 
et al., 2001). The aim of the present study was to determine the effects of cytokine TNF-α on the 
expression and function of P-glycoprotein in BME-UV cells. 
Materials and Methods 
Modulatory effects of TNF-α on gene expression in cultured BME-UV cells were 
determined by measuring mRNA and protein levels following exposure to TNF-α for different 
periods of time. Effects on the permeation of epithelial barrier were examined by performing 
diffusion studies using compounds known to interact with P-glycoprotein.    
Cell Culture 
The BME-UV cells were cultured under conditions similar to those described previously 
in details (Quesnell et al., 2007a; Schmidt et al., 2001). Briefly, the BME-UV cells were grown 
to 65-75% confluency in 25 cm2 plastic culture flasks (Corning, Corning, NY). Then, dissociated 
and dispersed cells were seeded on permeable polyester inserts, (Transwell, Corning) and fed 
with asymmetrical media. Typical bovine medium (TBM), which contains little lactose and has 
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concentrations of electrolytes that closely mirror serum, bathed the basolateral aspect of the cells 
throughout all experiments. The apical aspect was exposed to apical bovine medium (ApM) of 
low electrolyte-high lactose composition that resembles the ionic composition of milk. 
Composition of TBM and ApM were reported previously (Quesnell et al., 2007a; Schmidt et al., 
2001). The cells were incubated at 37°C in a humidified atmosphere containing 5% CO2. Media 
on both the apical and basolateral aspects of the cells were refreshed daily. Cells were 
maintained in culture on permeable supports for 2 weeks to form a confluent, polarized and 
electrically tight monolayer prior to all experiments.  
Incubation Conditions with Pro-Inflammatory Cytokine (TNF-α) 
Cells were grown to confluence and exposed to pathophysiologically relevant 
concentrations (200 ng/ml) of recombinant bovine TNF-α (Thermo Scientific, Rockford, IL) for 
24, 72, and 120 hours prior harvesting the cells for RNA isolation and protein production 
investigations, or using them in transport studies. TNF-α concentration within this range have 
been reported in dairy cows with mastitis (Bannerman, 2009; Hoeben et al., 2000). Paired cells 
were maintained without exposure to TNF-α (unexposed).  
Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
RNA Extraction 
RNA was isolated from confluent monolayers of BME-UV cells that were exposed to 
TNF-α for 24, 72 and 120 hour prior to harvesting the cells using RNeasy Mini kit (QIAGEN, 
Foster City, CA) according to the manufacturer’s directions. RNA concentrations were 
determined by the measurement of optical density at 260 nm (NanoDrop 8000, Thermo 
Scientific). Isolated total RNA integrity was verified by an OD260/OD280 absorption ratio greater 
than 1.8 and less than 2.0. Non-degraded and sufficiently concentrated RNA (~0.5 to 1.0 µg/µl) 
was used in RT-PCR assays. 
Primer Design for RT-PCR 
Bovine sequences of mRNA for each gene were obtained from the National Center for 
Biotechnology Information Genebank. Primer pairs (GGAGCCCATTCTGTTTGACT and 
TCCTTTGTCCCCTACTCTGG) to detect mRNA coding for bovine P-glycoprotein (bABCB1) 
and (AAGATTGTCAGCAATGCC and ACAGACACGTTGGGAG) to detect mRNA coding for 
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bovine GAPDH (bGAPDH) were chosen to give amplification product between 150 and 300 
base pairs using Primer3 software, a web-based primer design program. Both primer pairs were 
custom synthesized by Integrated DNA Technologies (Integrated DNA Technologies, Coralville, 
IA). 
RT-PCR  
The expression of bABCB1 in mammary epithelial cells was determined by RT-PCR 
(iCycler, Bio-Rad Laboratories, Hercules, CA) with the use of a commercial kit (Quantitect 
SYBR Green RT-PCR kit and reagents, Qiagen). Reactions were performed in a final volume of 
25 μL containing 100 ng of template RNA, 0.5 μM forward and reverse primers, 0.25 μL 
Quantitect RT Mix, 12.5 μL Quantitect SYBR Green (1x) and 8.25 μL RNase-free Water. 
Triplicate determinations were performed for each sample (three samples total) of each target 
gene (bABCB1 and bGAPDH) in a 96-well optical plate. This experiment was repeated four 
times on separate days. RT-PCR assays were conducted in the manner where samples of bovine 
kidney, no-template reaction and no reverse transcriptase were included in each assay.  
RT-PCR Protocol 
The RT-PCR protocol consisted of reverse transcription (50°C for 30 minutes), PCR 
initial activation (95°C for 15 minutes), followed by 40 cycles of denaturing at 94°C for 15s, 
annealing at 58°C for 30s, and extension at 72°C for 30s. A melt curve analysis from 65°C-95°C 
at 0.5°C/s was conducted immediately following PCR. Relative gene expression in different 
treatments to the average untreated was calculated using 2-∆∆CT method according to Livak and 
Schmittgen (2001).  
Western Blot 
The immunoreactive bands for P-glycoprotein were measured in plasma membrane 
fractions isolated from both unexposed and TNF-α exposed BME-UV cells on western blots by 
modifying a previously described method (Poller et al., 2010). Briefly, protein content was 
determined using a bicinchoninic assay (Thermo Scientific) and 30 µg of protein were resolved 
on 4-20% SDS-prepoured polyacrylamide gels (Thermo Scientific) and transferred to PVDF 
transfer membrane (Thermo Scientific). Membranes were blocked for 1 hour at room 
temperature with 5% powdered non-fat dry milk (Santa Cruz Biotechnology, Santa Cruz, CA) in 
 48 
phosphate buffered saline containing 0.1% Tween 20 (PBS-T). Washed membranes were 
incubated overnight at 4ºC with the monoclonal antibody, C219 (Covance, Denver, PA). Then, 
washed membranes were incubated for 1 hour at room temperature with horse-radish peroxidase-
conjugated goat anti-mouse IgG (1:1500) in PBS-T containing 5% non-fat dry milk powder. P-
glycoprotein immunorecativity was visualized using Femto-chemiluminescence substrate 
(Thermo Scientific). Gels were scanned (Kodak Image Station 4000R, Rochester, NY) and the 
intensity of the immunoreactive bands was quantified (Molecular Imaging software, Rochester, 
NY).  
Transport Studies 
Flow-Through Diffusion Cell System 
Confluent monolayers of BME-UV cells on permeable supports were mounted as a 
barrier in a flow-through diffusion cell system (Permegear, Bethlehem, PA). The system has 
automated receptor fluid collection and a high precision multichannel dispenser (Ismatec SA, 
Switzerland). The flow rate of receptor fluid through the receiver compartment of each diffusion 
chamber was controlled at 4 ml/h.  Temperature was maintained at 37°C by circulating water 
through the diffusion chambers holder. Donor compartments of diffusion chambers were capped 
directly after adding test solutions. Sequential samples were collected from the receiver side at 
regular time intervals (15 min) over a period of 120 min. Samples of either [14C]- or [3H]-
radiolabeled test compounds were assayed by dual labeled β-scintillation counting with quench 
correction  (Beckman LS6500, Beckman Coulter, Inc., CA). Automatic calculation of 
disintegrations per minute (DPM) was used for each sample.  
Digoxin Transport Studies 
[3H]-digoxin ([3H]-Digx), (American Radiolabeled Chemicals, MO), a compound known 
to interact with P-glycoprotein, was prepared in ApM together with [14C]-mannitol ([14C]-Mnt), 
(American Radiolabeled Chemicals). [14C]-Mnt was used as a marker for paracellular movement 
(Kimura et al., 2006). 
Study 1 
The apical to basolateral (Ap-to-BL) flux of digoxin across BME-UV monolayers that 
were exposed to pro-inflammatory cytokine TNF-α for 24, 72, and 120 hours was determined 
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and compared to unexposed cells. Transport experiments were initiated by adding 1 mL of test 
solution containing 0.05 µM of [3H]-Digx to the upper compartment (donor) together with 2µM 
[14C]-Mnt where the apical side of the epithelial monolayer facing the donor compartment with 
or without verapamil (Verp, 50 µM), (Sigma-Aldrich, St. Louis, MO), a compound known to 
interact with P-glycoprotein (Kim, 2002).  
Study 2 
The Ap-to-BL flux of digoxin across BME-UV monolayers that were exposed to pro-
inflammatory cytokine TNF-α for 72 hours was examined and compared to unexposed cells. 
This study was performed in the presence or absence of ketoconazole (Keto, 200 µM), (Sigma-
Aldrich), which is also known to interact with P-glycoprotein (Elsby et al., 2008; Keogh and 
Kunta, 2006) or probenecid (Prob, 200 µM), (Sigma-Aldrich), a compound known to interact 
with organic anion transporters (OAT) (Lash et al., 2007; Takeda et al., 2001).  
Data Analysis  
The digoxin flux (µmol/cm2 per hour) was calculated based on the amounts of digoxin 
recovered in the receiver compartment per unit time and then divided by mannitol flux at each 
measured time point to account for changes in overall epithelial integrity. Then, it was 
normalized by the effective diffusion area (cm2) of the cell culture insert.  
Statistical Analysis  
All statistical analyses were performed using the commercially available software 
SIGMASTAT (Systat Software Inc., San Jose, CA). Group comparisons were made by repeated 
measures ANOVA. When the ANOVA showed significant differences among treatments, the 
Holm-Sidak posttest (versus control) was performed to determine the specific treatment that is 
statistically significant different from the control (unexposed). The level of significance for all 
tests was set at P < 0.05. 
Results 
Influence of TNF-α on Monolayer Integrity 
The flux of mannitol across the BME-UV monolayer increased significantly after 24 and 
72 hours of TNF-α exposure (Table 5-1). However, the flux of mannitol decreased to values 
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indistinguishable from untreated after exposure to TNF-α for a longer time (120 hours), which 
may indicate the epithelial monolayers were able to restore their integrity. The lowest flux value 
of mannitol was in the unexposed monolayers (6.5 ± 0.7 x10-6 µmol/cm2 per hour), while the 
highest value was in the TNF-α exposed monolayers for 24 hours (15.5 ± 0.8 x10-6 µmol/cm2 per 
hour). 
Influence of TNF-α on ABCB1 mRNA Expression  
The results from RT-PCR analysis demonstrate a significant increase in the bABCB1 
mRNA expression after 24 hours of TNF-α exposure (Fig. 5-1). The mRNA levels were further 
upregulated after 72 hours of TNF-α exposure where it reached the maximum increase in mRNA 
expression (32 ± 2 %) compared to unexposed cells during the experiment. After 120 hours 
treatment with TNF-α, the increase in mRNA expression was 25 ± 6 %.    
Influence of TNF-α on the Expression of P-glycoprotein 
BME-UV cells exhibited different immunodetectable levels of P-glycoprotein after 
exposure to TNF-α for different periods of time as shown in Figs 5-2. A significant increase in P-
glycoprotein immunoreactive level was observed after 24 hours of TNF-α exposure. Longer 
exposure to TNF-α led to a further increase in immunoreactive protein levels that reached the 
maximum observed effect after 72 hours of TNF-α exposure. After 120 hours exposure of TNF-
α, the immunoreactive protein levels was increased significantly compared to the level of 
unexposed cells but it was lower than the level that was observed in the cells exposed to TNF-α 
for 72 hours.   
Influence of TNF-α on the Ap-to-BL flux of digoxin  
The apical to basolateral flux/time curves of digoxin across BME-UV cells treated with 
TNF-α for different durations are shown in the Fig. 5-3. The Ap-to-BL flux of digoxin across the 
epithelial monolayer was significantly decreased after 24 hours of TNF-α exposure. Similar 
consequences were observed after longer exposure to TNF-α (72 hours) where the flux of 
digoxin was decreased 43 ± 3 % compared to unexposed monolayers. The Ap-to-BL flux of 
digoxin after 120 hours of TNF-α exposure was decreased by 18 ± 8 %, which was not 
significantly different from digoxin flux across the unexposed cells (Fig. 5-3). 
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The normalized amount of digoxin that crossed unexposed BME-UV monolayers was 
nearly double the amount that crossed TNF-α exposed BME-UV monolayers. The highest 
intracellular content of digoxin was detected in the unexposed BME-UV cells (6.3 ± 2.6 x10-7 
µmol), while a lower intracellular content was observed in the TNF-α exposed cells for 24 hours 
(4.6 ± 1.1 x10-7 µmol) and the lowest level was observed after treating the BME-UV cells with 
TNF-α for 72 hrs (3.0 ± 0.2 x10-7 µmol). The recovery of digoxin from the entire system at the 
conclusion of experiment was 96 ± 2 %. 
Addition of verapamil to the donor compartment increased digoxin flux across TNF-α 
exposed BME-UV monolayers to the extent that there were no observable differences between 
exposed and unexposed cells (Fig. 5-4). Ketoconazole also increased digoxin flux across BME-
UV monolayers exposed to TNF-α for 72 hours. Probenecid (a compound known to interact with 
OAT) had no observable effect on digoxin flux across BME-UV monolayers, regardless of TNF-
α exposure (Figures 5-5).  
Rapid steady state conditions were attained quickly in less than 15 minutes. The whole 
system exhibits steady state activities over the experimental period of 2 hours. The results 
provide consistent evidence that the observations are related to the effect of TNF-α on P-
glycoprotein expression. The correlation between digoxin flux and mRNA expression or P-
glycoprotein immunoreactivity were both consistent as supported by regression (r2= 0.71 and 
0.65, respectively).   
Discussion 
Cytokine TNF-α exposure induced the expression of ABCB1 mRNA and increased P-
glycoprotein production in BME-UV cells. A significant decrease in the Ap-to-BL flux of 
digoxin across the TNF-α-exposed BME-UV monolayer was also observed. This latter 
observation can be attributed to the upregulation of P-glycoprotein in mammary epithelial cells, 
resulting in a greater efflux of digoxin back into the donor fluid. bABCB1 mRNA and P-
glycoprotein levels increased depending on the duration of exposure to TNF-α, with maximum 
levels at 72 hours. The observed changes in the expression level of both mRNA and P-
glycoprotein suggests that the effect of cytokine TNF-α on P-glycoprotein expression is at the 
transcription and translation level.     
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Mannitol flux increased across the BME-UV monolayer after exposure to TNF-α, 
suggesting that barrier function was compromised leading to an increase in paracellular solute 
flux. Similar results were observed by Quesnell et al (2007a), who studied the effects of pro-
inflammatory cytokines on the integrity of mammary epithelial monolayer (BME-UV) via 
analysis of transepithelial electrical resistance (Rte). They observed a 30% decrease in Rte value 
after exposure to TNF-α for 8 hours. By adding mannitol together with digoxin, we could 
account for this decrease in monolayer integrity by normalizing digoxin to mannitol flux. The 
resulting observations were therefore indicative of TNF-α associated changes in transcellular 
digoxin flux. 
Enhanced P-glycoprotein expression can explain the significant decrease in transcellular 
digoxin flux across the TNF-α-exposed BME-UV monolayers. The rate of digoxin efflux into the 
apical solution is proportioned to P-glycoprotein expression and activity or both, and the 
appearance of digoxin in the receiver compartment is inversely proportioned to P-glycoprotein 
activity. Verapamil and ketoconazole decrease this effect of TNF-α by either competing with 
digoxin or inhibiting the P-glycoprotein pump directly (Johnson et al., 2003; Kim, 2002).  
Probenecid reportedly has no effect on P-glycoprotein, but is known to affect the activity of other 
drug transporters including OAT. Thus, the absence of a probenecid effect further supports the 
notion that P-glycoprotein is responsible for digoxin flux across BME-UV cells. The differences 
in the intracellular contents of digoxin at the conclusion of experiment among different 
treatments were consistent with the other results in the current study. Enhanced P-glycoprotein 
expression in TNF-α-exposed mammary epithelial cells would pump more digoxin molecules out 
of the cells. Similarly, higher expression of P-glycoprotein would result in lower percentages of 
the administered digoxin dose crossing the BME-UV monolayer by the transcellular route, which 
is consistent with the observations in this study.  
Two molecular mechanisms account for the changes in P-glycoprotein transport activity 
and expression induced by TNF-α; changes in the dynamics of transporter trafficking, release 
from the internalized inactive state (vesicle), or increased synthesis of transporter protein (Bauer 
et al., 2007). Furthermore, the expressed protein can be in active or inactive states. Thus, 
understanding the molecular mechanisms of TNF-α induced effects may help us in explaining 
the inconsistency between the expression and function of P-glycoprotein in BME-UV cells. 
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A significant increase (different levels) in ABCB1 mRNA or protein production of P-
glycoprotein or both were observed in different cell culture models when cells were exposed to 
TNF-α for different periods of time. For example, immortalized human brain capillary 
endothelial cells (Poller et al., 2010), primary porcine brain capillary endothelial cells (Wedel-
parlow et al., 2009), and primary rat hepatocytes (Hirsch-Ernst et al., 1998). These results agree 
with our observations that the effect of TNF-α on the regulation of P-glycoprotein is dependent 
on the duration of TNF-α exposure. 
There are also studies that show opposing results. A decrease in ABCB1 mRNA and 
protein levels under the influence of TNF-α was reported in isolated primary placental 
trophoblasts (Evseenko et al., 2007) and human colon carcinoma cell lines, HCT15 and HCT116 
(Stein et al., 1996). These observations may be explained by the inter-species differences, the 
cell type in which transporter regulation was studied, as well as dose and exposure time of TNF-
α (McRae et al., 2003). Another important factor is the differences in the distribution of 
cytokines receptors among different types of cells (Yasumoto et al., 1992).  
Conclusion 
The results from the current study indicate that TNF-α induced bABCB1 mRNA and 
protein production of P-glycoprotein and decreased significantly the flux of digoxin across 
BME-UV cells. The regulation of P-glycoprotein in the mammary epithelium has important 
implications for understanding the barrier function of the mammary epithelium and provides 
insight into the role of P-glycoprotein in the accumulation and/or removal of specific substrates 
from milk and/or plasma. In the non-lactating mammary gland, P-glycoprotein levels may affect 
the mammary epithelial cells' exposure to xenotoxins as they accumulate on the apical side of the 
epithelial barrier. Moreover, this study provides an in vitro cell culture model of mammary 
epithelium to characterize mammary epithelial cell function during inflammation.     
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Figures and Tables 
 
Table 5-1. Mannitol flux across BME-UV monolayer from Ap-to-BL side 
 Treatments1 
 Unexposed TNF-24H TNF-72H TNF-120H 
Flux, µmol/cm2/hr 6.5 x 10-6a 15.5 x 10-6b 14.1 x 10-6b 9.6 x 10-6a 
SE2 0.7 x 10-6 0.8 x 10-6 1.1 x 10-6 1.5 x 10-6 
a–bMeans within a row with different superscripts differ (P < 0.05). 
1Treatments: BME-UV cells were exposed to cytokine TNF-α for 24- (TNF-24h); 72- (TNF-72h) 
and 120-hr (TNF-120H) prior to performing the transport study. 
2SE: standard error of the mean. 
 
 
 
 
Figure 5-1. bABCB1 mRNA expression in confluent TNF-α exposed BME-UV monolayers. 
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TNF-α exposure increases bABCB1 mRNA expression in confluent BME-UV monolayers. 
Monolayers were exposed to 200 ng/ml of TNF-α for 24, 72, and 120 hours before cells 
were harvested for RNA isolation. Star indicates the outcomes are statistically significant 
different from the vehicle. Data represents mean ± SE for n = 4, (P < 0.05).  
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Figure 5-2. Western blot analysis for P-glycoprotein band intensity in confluent TNF-α exposed 
BME-UV monolayers. 
 
 
 
 
 
 
 
  
Western blot analysis of total protein lysates identified significant changes in immunoreactive 
bands intensity of P-glycoprotein due to the exposure to TNF-α. Confluent BME-UV 
monolayers were exposed to TNF-α for 24, 72, and 120 hours before cells were harvested. 
Star indicates the outcomes are statistically significant different from the vehicle. Data 
represents mean ± SE for n = 5, (P < 0.05).    
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Figure 5-3. Ap-to-BL flux of digoxin across TNF-α exposed BME-UV monolayers.  
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Figure 5-4. Ap-to-BL flux of digoxin across TNF-α exposed BME-UV monolayers in the 
presence of verapamil. 
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TNF-α exposure, for 24 and 72 h, significantly (P < 0.05) decreases the mannitol-
normalized flux of digoxin across BME-UV monolayers. Digoxin flux across the BME-
UV monolayer from Ap-to-BL side after treating BME-UV cells with TNF-α for 24 
(TNF-24H); 72 (TNF-72H) and 120 hours (TNF-120H) prior to performing the 
transport study. Data represents mean ± SE for n = 3, (P < 0.05).   
Following exposure to TNF-α for the indicated durations, there were no significant 
differences in digoxin flux across the BME-UV monolayers in the presence of verapamil, 
a compound known to interact with P-glycoprotein. BME-UV cells were exposed to TNF-
α for 24 (TNF-24H); 72 (TNF-72H) and 120 hours (TNF-120H) prior to performing the 
transport study. Data represents mean ± SE for n = 3, (P < 0.05). 
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Figure 5-5. Ap-to-BL flux of digoxin across TNF-α-exposed and unexposed BME-UV 
monolayers in the presence and absence of ketoconazole and probenecid. 
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Ketoconazole but not probenecid increased significantly (P < 0.05) the mannitol-normalized 
flux of digoxin across the TNF-α-exposed and unexposed BME-UV monolayers. Mannitol-
normalized flux of digoxin (TNF_Digx or Vehicle_Digx) across the BME-UV monolayer from 
Ap-to-BL side. BME-UV cells were exposed to TNF-α for 72 hours prior to performing the 
transport study in the presence or absence of ketoconazole (TNF_Keto or Vehicle_Keto) or 
probenecid (TNF_Prob or Vehicle_Prob). Data represent mean ± SE for n = 3, (P < 0.05). 
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CHAPTER 6 - RESEARCH CONCLUSION AND FUTURE 
DIRECTIONS 
The study described in chapter 3 was designed to study the potential contributions of 
bOAT and bOCT in the movements of compounds across BME-UV cells.  By using a flow-
through diffusion cell system, functional expression of organic anion and cation transport 
systems was demonstrated in BME-UV cells. A similar polarized transport process for TEA has 
been identified previously in human mammary epithelial monolayers and attributed to the human 
OCT (Kimura et al., 2006). Furthermore, mRNA transcripts for 19 different transporter genes 
including OCT have been reported in rat whole mammary gland, and in non-lactating and 
lactating human mammary epithelia (Alcorn et al., 2002; Gilchrist and Alcorn, 2009). The 
expression of members of the OCT and OAT family members on the membrane of the BME-UV 
cells may relate to a physiological role of these transporters in milk production. Conversely, they 
may impart a protective role to the lactating mammary gland exuding potentially toxic 
xenobiotics into milk. But this increases the risk of milk residues that are potentially harmful to 
suckling off-spring or the human consumer. 
The Bronaugh-type flow-through diffusion cell system that was used in this study has 
numerous advantages over the static systems. The system allows for automatic sampling of 
receiver fluid to monitor the absorption/time profile accurately. Most importantly, receiver fluid 
flow maintained effective infinite sink conditions in the receiver compartment throughout the 
experiment, which reduces the effect of test compound molecules diffusing back from the 
basolateral to the apical side or vice versa (Bronaugh and Stewart, 1985). This is the first study 
using a cell culture in vitro model of bovine mammary epithelial cells to study the mechanisms 
of xenobiotic movement across epithelial barrier.  
To characterize the organic anion transport system expressed in BME-UV cells (chapter 
3), molecular and functional approaches were used to identify the isoforms of organic anion 
transporter (bOAT-1, bOAT-2, bOAT-3 and bOAT-4) (chapter 4). Expression levels of all tested 
transporters in BME-UV cells were less than expression levels of the corresponding transporters 
in bovine kidney, one of the major routes of organic anion elimination, by at least 2 orders of 
magnitude. Directionality in the flux of P-aminohippuric acid (Pah) and acetylsalicylate (Sal), 
compounds known to interact with OAT-1 and OAT-2 respectively, across the BME-UV 
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monolayer was not observed at the concentrations used in this study. This may be explained by 
low expression of the transporters for these compounds in BME-UV cells. Directionality was, 
however, observed in the flux of EsS across the BME-UV monolayer; this could be attributed to 
the involvement of the organic anion transport system in the molecules’ passage across BME-
UV cells.  
The flux of different anionic compounds known to interact with OAT in the in vitro cell 
culture model (BME-UV) is consistent with other observations regarding lactating cows and 
other species such as the rat. Experimental and theoretical (calculated on the basis of pH partition 
concept) milk-to-plasma ultra-filtrate ratios were in close agreement for Pah and Sal and not 
altered by drug concentrations or probenecid (Gerk et al., 2001a; Miller et al., 1967), which 
agree with our results in which directionality in the flux of both tests compounds was not 
observed. The milk concentration of endogenous EsS in bovine was significantly greater than 
that in plasma, indicating that EsS was actively transferred from blood to milk against a 
concentration gradient (Heap et al., 1983, 1984), which supports our hypothesis that EsS cross 
mammary epithelial barrier by a carrier mediated process.  
P-glycoprotein (the ABCB1 gene product, which was formally known as MDR1) plays an 
important role in xenobiotic absorption, distribution, and elimination as a result of its tissue 
distribution and cellular localization. In chapter 5, modulatory effects of TNF-α on P-
glycoprotein expression in cultured BME-UV cells were determined by measuring mRNA and 
protein levels following exposure to TNF-α for different periods of time. Effects on the 
permeation of the epithelial barrier were examined by performing transport studies using 
compounds known to interact with P-glycoprotein. Cytokine TNF-α exposure induced the 
expression of ABCB1 mRNA and increased P-glycoprotein production in BME-UV cells. A 
significant decrease in the Ap-to-BL flux of digoxin (P-glycoprotein substrate) across the TNF-
α-exposed BME-UV monolayer was also observed. 
A significant increase (different levels) in ABCB1 mRNA and/or protein production of P-
glycoprotein was observed in different cell culture models when cells were exposed to TNF-α for 
different periods of time (Hirsch-Ernst et al., 1998; Poller et al., 2010; Wedel-parlow et al., 
2009). These results agree with our observations that the effect of TNF-α on the regulation of P-
glycoprotein is dependent on the duration of TNF-α exposure. 
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Implications 
Taking the results together, the dynamic nature of the BME-UV monolayer has been 
confirmed in the current research by providing data regarding the expression, function, and 
regulation of members of OCT, OAT, and P-glycoprotein in BME-UV cells, a model for the 
blood-milk barrier. 
The functional expression of members of bOCT and bOAT subfamilies in BME-UV cells 
may indicate the pivotal role of these transport systems in the function of mammary epithelial 
cells, translocation of molecules, endogenous and exogenous compounds and their metabolites, 
between plasma and milk.  
The expression and regulation of P-glycoprotein in the mammary epithelium, expressed 
at low levels during lactation and at high levels during the dry period (Alcorn et al., 2002; 
Gilchrist and Alcorn, 2009), has important implications for understanding the barrier function of 
the mammary epithelium and its role in protecting the mother (mainly during lactation) from 
potentially harmful xenobiotics. The active efflux of P-glycoprotein substrates into milk may 
expose nursing infants and milk consumers to potentially harmful compounds. This exposure 
may be increased if the mammary gland was to become inflamed. In the non-lactating mammary 
gland, P-glycoprotein levels may affect the mammary epithelial cells' exposure to xenotoxins as 
they accumulate on the apical side of the epithelial barrier. This exposure may lead to dangerous 
consequences because mammary tissue possess enzymes capable of activating drugs and 
xenobiotic agents that may contribute to breast cancer and other diseases through formation of 
genotoxic agents in breast tissue (McManaman and Neville, 2003).  
Exposure to pro-inflammatory cytokine TNF-α led to changes in the function of the 
mammary epithelial barrier as demonstrated by changes in the expression of P-glycoprotein (up-
regulation) and the flux of mannitol, a paracellular marker, and other test compounds.  
The relative importance of different membrane transporters in the milk excretion of 
compounds in vivo remains unknown and will require further studies. This study provides a cell 
culture in vitro model of bovine mammary epithelium that may be considered as a first step on 
the pathway of improving our understanding of the mechanisms by which xenobiotics move 
across the mammary secretary epithelium.  
Future directions 
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Further investigations in the role of mammary gland transporters in the transepithelial 
movement of nutrients into the milk are greatly needed. Knowing the substrate (xenobiotic or 
nutrient) profile of mammary gland transporters will provide insight into the possibilities of 
xenobiotic-nutrient transporter interactions. For example, one of the physiological functions of 
ABCG2 has been observed to be the secretion of vitamin B2 (riboflavin) into breast milk 
(Vlaming et al., 2009). Moreover, repeated exposure to dietary ingredients such as capsaicin, 
daidzein, piperine and sesamin can cause drug-nutrient interactions by affecting the function and 
mRNA expression of intestinal transporters such as P-glycoprotein (Okura et al., 2010). Thus, 
screening for these interactions will add another assessment tool to help safeguard infant and 
milk consumer health by preserving the high quality composition of milk.  
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